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Abstract
The growth and survival of a malignant tumor is dependent on its ability to 
induce the formation and to maintain its own microvasculature. Inhibition of this 
process termed tumor angiogenesis is an emerging strategy in cancer therapy. The 
extracellular matrix surrounding the vascular endothelial cells contains cryptic 
domains, which are exposed and released by changes in the proteolytic 
homeostasis of the tumor microenvironment. These fragments transmit local 
signals regulating vascular endothelial cell proliferation and migration. 
Endostatin, the proteolytic fragment of collagen type XVIII, is a potent inhibitor 
of tumor angiogenesis in various mouse models and is currently in clinical trials 
for therapeutic use in human cancer. 
To understand the nature of the inhibitory effects of human endostatin on 
angiogenesis, we studied the cell biological mechanisms contributing to the anti-
migratory and anti-proliferative effects of endostatin on cultured human 
microvascular endothelial cells. We observed that endostatin effectively regulates 
the pericellular proteolysis of endothelial cells by downregulating the levels of 
soluble secreted urokinase-type plasminogen activator (uPA) and its inhibitor, 
plasminogen activator inhibitor-1 (PAI-1). In addition, the cell surface localization 
of uPA/PAI-complexes was altered, and they accumulated on the cell surface. 
These changes were accompanied by the disassembly of focal adhesions and actin 
stress fibers. The disassembly of the cytoskeletal structures was associated with 
the tyrosyl phosphatase-dependent activation of Src tyrosine kinase. Src activation 
resulted also in altered deposition of the endothelial cell fibronectin matrix and 
decreased migratory capacity of these cells. Our results further indicated that the 
intracellular events leading to the cytoskeletal changes were a consequence of 
endostatin interaction with integrin α5β1, caveolin-1 and a heparan sulfate 
proteoglycan. Facilitated by these interactions, a fraction of endostatin partitioned 
to lipid rafts, membrane microdomains specialized in signal transduction. The 
binding of endostatin to integrin α5β1 and cell surface heparan sulfates resulted in 
the Src-dependent activation of p190, subsequent downregulation of RhoA 
activity, and finally the disassembly of the actin cytoskeleton. 
We generated synthetic peptides derived from the amino terminus of 
endostatin and analyzed their effects on endothelial cell adhesion and migration. 
The peptides promoted cell adhesion via integrin β1 and induced cytoskeletal 
changes comparable to the effects of full-length endostatin. The peptides also 
inhibited directional migration and tubular morphogenesis of endothelial cells. 
The current results identify a novel mechanism, by which a fragment of an 
extracellular matrix component transmits signals to the endothelial cell cytoplasm 
and regulates multiple functions of endothelial cells. 
 10
Introduction 
Angiogenesis, the formation of new blood vessels, is a hallmark of cancer. 
Without developing a functional vasculature, tumors are unable to grow beyond a 
microscopic size or metastasize to distant organs. The process of angiogenesis 
involves complex cellular and molecular mechanisms initiated by a shift in the 
balance of pro- and anti-angiogenic molecules. Subsequently, cellular programs 
regulating endothelial cell proliferation, migration, extracellular matrix (ECM) 
degradation, and differentiation are initiated, leading to vessel sprouting from 
existing vessels. Inhibition of these processes is an emerging strategy of cancer 
therapy. Endogenous anti-angiogenic molecules have been isolated and are 
currently in clinical trials to be used alone or in combination with conventional 
therapies in the treatment of cancer as well as other diseases involving 
pathological angiogenesis. 
Cell migration and extracellular matrix 
Most cell types are able to move within their tissue compartment, while some 
highly motile cells are capable of penetrating through tissue boundaries such as 
basement membranes (BM). In multicellular organisms cell migration plays an 
important role in fundamental processes such as embryonic development, 
immunological defense mechanisms, trophoblast invasion, and wound healing. In 
addition, it is an important cascade of events in pathological conditions such as 
tumor invasion and metastasis (Lauffenburger and Horwitz, 1996). 
Extracellular matrix 
Most cells in multicellular organisms are surrounded by an organized 
meshwork of macromolecules that constitute the extracellular matrix (ECM). The 
ECM functions as a structural framework and provides cells with positional and 
environmental information, but also forms specialized structures such as cartilage, 
tendons, BMs, bone and teeth. In addition, it regulates multiple aspects of cell 
behavior, such as their development, migration, proliferation, shape, and 
metabolic functions. 
The ECM is not a static structure, but is continually produced and remodeled. 
The macromolecules of the ECM are secreted by local cells such as fibroblasts. 
Two of the main classes of extracellular proteins that make up the matrix are the 
collagens and the proteoglycans. The long collagen fibers strengthen and organize 
the matrix, while the polysaccharides of the proteoglycans form an aqueous phase, 
which permits the diffusion of nutrients, metabolites, and hormones between 
tissue compartments. Elastin is a component of fibers, which confer matrix 
resilience. In addition, two high molecular glycoproteins, fibronectin and laminin 
are among major components of the ECM. Fibronectin is widely distributed in 
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connective tissues, whereas laminin is found exclusively in the BM. 
Collagens are among the most abundant proteins in mammals and the most 
abundant protein in the ECM. All the 23 vertebrate collagens are composed of 
three α-chains and contain at least one triple-helical domain of repeating glycines 
(Gly-X-Y motif). The triple helix is a rigid structure, but it is interrupted in many 
collagens by non-triple helical domains that provide flexibility (Prockop and 
Kivirikko, 1995). 
Fibronectin is a large, dimeric glycoprotein that is produced by most cell 
types. It exists in two major forms, as a soluble form in the plasma and other body 
fluids and as an insoluble form in the ECM. Insoluble fibronectin plays a critical 
role in embryonic development, as adhesion of embryonic cells to fibronectin is 
essential for their migration (George et al., 1993). The deposition of fibronectin is 
a cell-dependent event initiated with binding of soluble fibronectin to cell surface 
integrins (Mosher et al., 1991; Schwarzbauer and Sechler, 1999; Wu, 1997). 
Fibronectin interacts with integrins mainly through the RGD-sequence, but also 
other sites are involved (Miyamoto et al., 1998). Fibronectin is also deposited to 
the ECM by endothelial cells to provide support in cell migration and adhesion 
during angiogenesis, and is thus important both in developmental and pathological 
angiogenesis (George et al., 1997; Kim et al., 2000a). Vitronectin, 
thrombospondin, tenascin, and SPARC (secreted protein, acidic and rich in 
cysteine) are other ECM glycoproteins involved in mediating both adhesive and 
anti-adhesive interactions and also in the regulation of angiogenesis (Adams, 
2001; Bradshaw and Sage, 2001; Murphy-Ullrich, 2001; Schvartz et al., 1999). 
Basement membranes 
Basement membranes (BM) are dense sheets of extracellular matrix that 
function as structural barriers separating epithelial and endothelial cells as well as 
peripheral nerve axons, fat cells and muscle cells from the underlying tissue 
stroma. BMs provide structural support, separate tissues into compartments, and 
regulate cell behavior (Timpl, 1996). All cell types are known to produce 
components of BMs, which include type IV collagen, laminin, heparan sulfate 
proteoglycans and nidogen/entactin. Minor components include agrin, SPARC, 
fibulins, type XV collagen and type XVIII collagen. Fibronectin is present in fetal 
BMs (Erickson and Couchman, 2000; Ghohestani et al., 2001). The molecular 
composition of the BM varies among different tissues. The differences are 
believed to confer tissue specificity, which is important for defining the 
specialized functions of epithelial and endothelial cells in different organs. 
Type IV collagen is the major collagen found in basement membranes. It is 
composed of three parallel α chains, which form a triple helical structure with 
interruptions. Six different α chains have been identified, and they can form 56 
different combinations of collagen trimers (Hudson et al., 1993). Type IV forms a 
network-like structure that is associated with perlecan and, via nidogen, with the 
laminin network. Structural studies have indicated that type IV collagen network 
formation is crucial for BM stability and assembly (Kuhn, 1995; Timpl, 1996). 
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Laminins are major contributors to BM assembly and the resulting 
supramolecular structure. They are a family of at least 15 heterotrimeric 
glycoproteins composed of five α, three β, and three γ subunits. The various 
laminin isoforms have a cell and tissue-specific expression pattern and are 
differentially recognized by their integrin receptors. Via interactions with various 
integrin as well as non-integrin receptors, laminins display a large repertoire of 
biological functions, such as regulation of tissue morphogenesis, cell migration 
and differentiation and wound healing (Colognato and Yurchenco, 2000). 
Type XVIII collagen is a component of several different types of epithelial 
and vascular BMs. The collagen molecule consists of 10 triple-helical domains 
that are separated by non-triple-helical (NC) regions (Fig. 1)(Oh et al., 1994). The 
collagen 18 gene encodes for two 1516 or 1336 amino acid residue variant
α1(XVIII) chains, which are expressed in a tissue specific manner. The two 
chains have different signal peptides and variant N-terminal noncollagenous NC1 
domains, but share multiple triple-helical domains that are separated by non-
triple-helical regions. The longer form has a cystein-rich motif homologous to the 
extracellular part of the frizzled receptors involved in the Wingless signaling 
pathway in Drosophila. The longer splice variant is mainly expressed in the liver, 
whereas the shorter variant is virtually absent from the liver, but is a ubiquitous 
component of vascular and epithelial BMs throughout the body (Saarela et al., 
1998a). α1(XVIII) mRNAs are produced by several cell types, including 
epithelial and endothelial cells, cardiac muscle cells, keratinocytes, and 
hepatocytes (Saarela et al., 1998b). Collagen XVIII is also a heparan sulfate 
proteoglycan, which serves as a ligand for the receptor tyrosine phosphatase σ
(Aricescu et al., 2002). 
Figure 1. Schematic structure of type XVIII collagen. Ten collagenous domains are interrupted by 
11 NC domains. The long isoform contains the alternatively spliced Frizzled domain. The NC1 
domain contains the trimerization domain, the protease sensitive hinge domain and the 20 kDa 
endostatin fragment (Oh et al., 1994). 
Type XVIII collagen is believed to contribute to the normal development of 
vasculature in the retina. A mutation in human collagen XVIII has been associated 
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with Knobloch syndrome, a disease characterized by a failure in the development 
of retinal vasculature, retinal degeneration and blindness (Sertie et al., 2000). 
Mice deficient in type XVIII collagen are viable and fertile, and display no major 
vascular abnormalities. However, a defect in the regression of hyaloid vessels is 
observed (Fukai et al., 2002; Ylikärppä et al., 2003a). In addition, these mice 
develop age-dependent loss of vision, which is due to the deposition of electron 
dense material in the sub-retinal pigment epithelium. This results in disturbances 
in vitamin A metabolism and photoreceptor function, suggesting that type XVIII 
collagen is essential for retinal pigment epithelium function (Marneros et al., 
2004).
The C-terminal NC domain of collagen XVIII contains the anti-angiogenic 
fragment known as endostatin. The endostatin domain is separated from an 
upstream trimerization region by a hinge domain. Proteolytic cleavage within the 
hinge region results in the release of monomeric endostatin (O'Reilly et al., 1997). 
Type XV collagen is highly homologous to type XVIII collagen, consisting 
of a central triple-helical domain interrupted by NC domains (Muragaki et al., 
1994; Myers et al., 1992). It is also expressed in the BM of blood vessels 
(Muragaki et al., 1995). The vasculature and the vascular BM develop normally in 
mice deficient in type XV collagen, but collapsed capillaries and endothelial-cell 
degeneration in the heart and skeletal muscle are observed, indicating that 
collagen XV plays a role in stabilizing the microvasculature and skeletal muscle 
cells (Eklund et al., 2001). Despite significant structural homology and 
overlapping expression patterns, collagens XV and XVIII seem to have separate 
biological roles. The double knockout mice for the two collagens do not have any 
additional major defects apart from the ones found in the single knockouts 
(Ylikärppä et al., 2003b). 
Mechanisms of cell motility 
Cell motility can be regulated at multiple levels. In general, it is regulated 
through interactions of molecules expressed on the cell surface with the 
surrounding tissue microenvironment. The initial step of cell motility is 
polarization, i.e. establishment of the front and rear of the cell. This involves 
redistribution of filamentous actin, cell adhesion molecules such as integrins, as 
well as chemokine receptors. In addition, membrane protrusions, lamellipodia and 
filopodia, extend at the cell front as a result of actin polymerization. 
Concomitantly, new cell-matrix adhesions are formed at the leading edge. The cell 
migrates over the adhesion complexes until they reach the cell rear, where they 
are disrupted and the adhesion subsequently detaches (Fig. 2). Two distinct types 
of force move the cell body forward: the protrusive force needed to extend 
lamellipodia and filopodia, and the contractile force needed to move the cell body 
forward. These forces are generated by actin filament contraction and traction 
from the cell-substratum adhesions (Lauffenburger and Horwitz, 1996). The 
strength of cell adhesion to the ECM regulates the choice between adhesion and 
migration. If the adhesion is too strong, the cell remains stationary, and if the 
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adhesion is too weak, enough traction cannot be generated for movement. 
Migration occurs thus at intermediate levels of adhesion, which can be achieved 
by regulating the expression levels of cell adhesion molecules or their 
extracellular ligand, as well as by modulating the activation status of the receptors 
(Schwarzbauer, 1997). 
The strength of cell adhesion in migrating cells can also be regulated by 
proteins in the extracellular environment. While several ECM components 
promote cell adhesion, there are a number of proteins with anti-adhesive 
functions. Proteins with anti-adhesive properties include tenascin-C, 
thrombospondin-1, SPARC, and latent transforming growth factor-β binding 
protein-2. These proteins induce a rapid transition to an intermediate state of 
adhesiveness characterized by altered cell morphology and cytoskeletal structures 
(Hyytiäinen and Keski-Oja, 2003; Murphy-Ullrich, 2001). 
The direction of cell movement is controlled by growth factors such as bFGF 
and VEGF. These growth factor signals are transmitted into the cytoplasm via 
receptor tyrosine kinases, which engage in extensive crosstalk with specific 
adhesion molecules such as integrins to induce changes in intracellular signaling, 
gene expression levels, and proteolytic cascades to enhance cell polarization and 
directed cell motility (Eliceiri, 2001; Schwartz and Baron, 1999). 
Figure 2. Integrin-mediated adhesion and focal adhesion assembly in cell motility. Cycles of cell-
ECM attachment and detachment together with the contraction of the actin cytoskeleton move the 
cell body forward. Ligand binding and clustering of integrins at the leading edge activate 
signaling proteins such as FAK, Src, and RhoA, which regulate the assembly and disassembly of 
focal adhesion complexes as well as actin stress fiber dynamics. New adhesion complexes are 
formed at the leading edge. The cell subsequently migrates over the complexes, which translocate 
to the cell rear where they are disassembled. Modified from (Gumbiner, 1996). 
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Integrins and cell-matrix interactions 
Integrins are heterodimeric transmembrane receptors, which bind to ligands 
in the extracellular matrix or counter-receptors on adjacent cells. The mammalian 
family of integrins consists of at least 16 α and 8 β subunits, which are able to 
noncovalently heterodimerize into approximately 24 receptors with distinct, but 
often overlapping substrate specificities (Hynes, 2002a). ECM or cell surface 
proteins containing the Arg-Gly-Asp (RGD) sequence constitute the major class 
of integrin ligands. Integrins that recognize this sequence include the major 
fibronectin receptor α5β1 integrin and vitronectin receptors αvβ3 and αvβ5
(Ruoslahti, 1996). Integrins function as transmembrane links between the ECM 
and the actin cytoskeleton. In addition to regulating cell adhesion to the ECM, 
integrins are involved in transmitting signals, which regulate cell shape, survival, 
proliferation, gene transcription, and migration (Aplin et al., 1999). 
Integrins not occupied by a ligand are distributed diffusely over the cell 
surface and are not linked to the cytoskeleton. Upon ligand binding, integrins 
cluster into specialized adhesive structures called focal contacts and become 
associated with the actin cytoskeleton. Monovalent ligand occupancy can in some 
cases trigger an intracellular response, but for efficient accumulation of 
cytoskeletal proteins clustering is additionally required (Miyamoto et al., 1995). 
The assembled focal contacts undergo tyrosine phosphorylation events and 
subsequently mature into stable multiprotein complexes called focal adhesions 
(Luna and Hitt, 1992; Sastry and Horwitz, 1993; Schoenwaelder and Burridge, 
1999). Focal adhesions comprise of a large number of proteins with both 
structural and signaling function. A large number of the proteins bind directly to 
actin and function at different stages of the adhesion complex maturation cycle. 
The most abundant structural focal adhesion proteins include vinculin, talin, and 
paxillin. The most common integrins found in these adhesions are α5β1 and αvβ3,
although others are present on substrates like collagen (Jockusch et al., 1995). The 
multiprotein adhesion complexes regulate cell attachment, migration, and 
signaling on extracellular substrates as well as the composition and assembly of 
the ECM (Geiger et al., 2001). 
Signaling pathways involved in cell migration 
Cell migration involves dynamic changes in cell - matrix interactions. Focal 
contacts are constantly assembled and disassembled as the cell moves across the 
ECM. This regulation requires complex signaling downstream of the adhesion 
receptors. Intracellular signaling is often mediated by covalent modifications, 
which activate or inactivate proteins, and thus act as molecular switches. Such 
modifications include protein phosphorylation and conformational changes that 
expose cryptic sites for subsequent protein-protein interactions (Hunter, 2000). 
Focal adhesion kinase (FAK) and Src are molecular switches involved in the 
transmission of intracellular signals from extracellular cues via direct interaction 
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with the cytoplasmic tails of integrins (Fig. 2)(Parsons et al., 2000; Thomas and 
Brugge, 1997). They form a molecular complex involving regulation of activity 
both via autophosphorylation and phosphorylation of each other. Both molecules 
subsequently phosphorylate various focal adhesion target proteins. Src-FAK- 
mediated phosphorylation has a dual role in regulating focal adhesion dynamics 
and turnover, as it can both stimulate the recruitment of proteins in to the complex 
and induce the disassembly of these structures (Felsenfeld et al., 1999; Volberg et 
al., 2001). 
The key molecules regulating actin polymerization and focal adhesion 
assembly downstream of FAK and Src are the Rho family of GTPases. At least 10 
members are known to exist in mammals: RhoA-E, RhoG, Rac1-2, Cdc42 and 
TC10 (Kaibuchi et al., 1999). The Rho proteins cycle between two conformational 
states: the active GTP-bound and inactive GDP-bound form. In the active form 
they are able to interact with downstream target proteins and generate signaling 
responses, after which they return to the inactive state through intrinsic GTPase 
activity. The GTPase activity is enhanced by their interaction with GTPase 
activating proteins (GAPs). These molecules are in turn regulated by tyrosine 
phosphorylation by kinases such as Src (Bishop and Hall, 2000). The most 
extensively characterized members of the Rho family are RhoA, Rac and Cdc42. 
Each of them acts in a spatially and temporally coordinated manner to regulate 
separate aspects of contractile actin and myosin filament assembly. 
Rac induces actin polymerization at the cell periphery, leading to the 
formation of membrane protrusions called lamellipodia. Rac also promotes the 
formation of integrin-containing adhesion complexes at the leading edge of 
migrating cells (Ridley et al., 1992). These processes are essential for the 
migration of all cell types, and loss of Rac results in the inhibition of cell motility 
(Small et al., 2002). RhoA in turn stimulates the formation of actin stress fibers 
and focal adhesions (Ridley and Hall, 1992). The balance of RhoA activity in 
migrating cells is tightly regulated in order to maintain the state of intermediate 
cell adhesion. RhoA activity thus plays a dual role in both promoting and 
inhibiting migration. Cdc42 promotes the formation of thin, finger-like membrane 
protrusions called filopodia (Nobes and Hall, 1995). In addition, Cdc42 has an 
important role in directed cell movement, possibly through stabilization of Rac at 
the cell front. Loss of Cdc42 activity does not block cell motility, but results in 
random migration (Allen et al., 1998). 
In addition to bioactive lipids, peptides and growth factors, RhoGTPases are 
activated via integrin-mediated cell adhesion. Binding of integrins to their ECM 
substrates promotes actin polymerization and formation of filopodia and 
membrane ruffles via Rac and Cdc42. RhoA is also activated in response to 
integrin ligation (Clark et al., 1998; Price et al., 1998). 
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Pericellular proteolysis 
Various physiological processes require coordinated tissue remodeling. 
Degradation of the ECM is involved in tissue morphogenesis and growth as well 
as angiogenesis, bone remodeling wound healing, trophoblast implantation, and 
involution of the postpartum uterus or postlactation mammary gland. In addition, 
proteolysis is involved in pathological conditions such as tumor growth, invasion, 
and metastasis, chronic wounds, arthritis and other autoimmune diseases (Johnsen 
et al., 1998; Werb, 1997). The ECM is not the only target for pericellular 
proteolysis, as cell surface proteins, receptors, and transmembrane ECM proteins 
are also regulated by proteolysis (Werb et al., 1999). 
ECM degradation in vivo occurs in a spatially confined manner in the 
immediate pericellular environment of cells. This can be achieved by targeting the 
proteolytic enzymes to the cell membranes and into specific microdomains within 
the membranes. The targeting occurs via distinct mechanisms. Soluble enzymes 
are bound to specific receptors on the cell surface. Proteinases with 
transmembrane domains contain sequences that localize them to adhesion sites or 
invasive protrusions. In addition, interactions with other cell surface molecules 
such as integrins modulate the localization of cell surface proteinases (Basbaum 
and Werb, 1996). 
Degradation of ECMs and BMs involves concerted activity of numerous 
proteinases. They are classified into exo- or endopeptidases according to the 
terminal or internal cleavage site on their substrate proteins. The endopeptidases 
are further divided into subgroups of serine, cysteine, aspartic and 
metalloproteinases according to sequence homology and cofactors determining 
their catalytic activity. 
Plasminogen activators 
The plasminogen activator / plasmin system is composed of plasminogen and 
two plasminogen activators, urokinase-type plasminogen activator (uPA) and 
tissue-type plasminogen activator (tPA), plasminogen activator inhibitors (PAI), 
and receptors. The activation of the zymogen plasminogen into the active 
proteinase plasmin occurs through proteolytic cleavage of a single peptide bond 
by the plasminogen activators. Plasmin is primarily involved in the proteolysis of 
the fibrin clot, but is also capable of degrading various components of the ECM. 
All the components of the plasminogen activator system are anchored to the 
cell surface via specific receptors, enabling their function in targeted pericellular 
proteolysis and processes such as tissue morphogenesis, angiogenesis, 
arteriosclerosis and tumorigenesis (Ellis, 2003). 
The activity of tPA is stimulated by and localized to the fibrin matrix due to a 
high-affinity interaction between the finger-kringle domains of tPA and the 
polymerized fibrin. This property makes tPA important in intravascular 
fibrinolysis (Stubbs et al., 1998). In contrast, uPA is mainly involved in cell 
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migration, invasion, and tissue remodeling due to its specific targeting to the cell 
surface (Ellis et al., 1989). 
Urokinase-type plasminogen activator 
The serine proteinase uPA is a 55 kDa polypeptide consisting of two 
disulfide-linked chains, a C-terminal B chain containing the serine proteinase 
domain, and an N-terminal A chain containing the growth factor-like domain, a 
kringle domain and an interdomain linker region. The single-chain form of uPA is 
an inactive zymogen, which is proteolytically cleaved to yield the active two-
chain form. The cleavage can be carried out by plasmin and several other 
proteinases (Andreasen et al., 2000). 
Through the activation of plasminogen and its intrinsic proteolytic activity 
uPA is able to degrade fibrin, laminin, fibronectin, proteoglycans, gelatin and 
thrombospondin. Importantly, native collagens are resistant to proteolysis by uPA 
or plasmin (Danø et al., 1985; Kwaan, 1992). In addition, uPA/plasmin catalyze 
the activation of several growth factors such as hepatocyte growth factor and 
transforming growth factor-β. They also activate other proteolytic enzymes, such 
as matrix metalloproteinases (MMP). The zymogens for MMP-3, -9, and -8 have 
been shown to be physiological substrates for uPA/plasmin using plasminogen 
activator deficient mice (Andreasen et al., 2000). 
Most tissues express low levels of uPA. The expression occurs mostly in 
tissues undergoing remodeling. Epithelial cells in the kidney produce measurable 
amounts of uPA, while alveolar epithelial cells produce uPAR that can recruit 
uPA. In these compartments the uPA system may be used to catalyze the lysis of 
microthrombi (Solberg et al., 2001; Wagner et al., 1996). uPA is constitutively 
expressed in endothelial cells of various tissues and it is up-regulated by various 
angiogenic growth factors, transforming growth factor-β and hypoxia (Graham et 
al., 1998; Laiho et al., 1986; Laiho and Keski-Oja, 1989; Pinsky et al., 1998). 
Urokinase receptor 
uPA is targeted to the cell membrane via a specific cell surface receptor, 
uPAR. Pro-uPA and active two-chain uPA bind uPAR with similar affinity (Kd< 1 
nM). The binding of pro-uPA to uPAR facilitates its activation to uPA, localizing 
plasminogen activation to the cell surface (Fig. 3)(Andreasen et al., 2000). uPAR 
binds also the plasma and ECM protein vitronectin via an interaction dependent 
on the presence of uPA (Waltz and Chapman, 1994). The uPAR protein is 
composed of three internally repeated sequence motifs (D1, D2, and D3), which 
are attached to the plasma membrane by a glycosylphosphatidylinositol (GPI) 
moiety. The GPI anchor can be cleaved to release soluble uPAR. In addition, 
cleavage can occur between D1 and D2 domains to yield D1 and D2D3 
fragments. D2D3 has been shown to have chemotactic properties (Blasi, 1999). 
The GPI anchor as a mode of membrane attachment has a critical impact on 
the functional properties of uPAR. Interactions with various transmembrane 
proteins to form functional complexes compensate for the lack of direct 
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interaction between uPAR and the cytoplasm. The internalization of the receptor-
ligand complexes is mediated via interaction with the low-density lipoprotein-
receptor-related protein (Czekay et al., 2001) In addition, the GPI-anchor 
regulates the partitioning of uPAR into lipid rafts, which are specialized 
membrane microdomains that serve as foci for the recruitment of transmembrane 
proteins and intracellular signaling molecules (Simons and Toomre, 2000). 
Intracellular signaling by uPA and uPAR, on the other hand, are mediated mainly 
by direct interactions of uPAR with integrins, caveolin, and G-protein-coupled 
receptors (GPCR) (Resnati et al., 2002; Wei et al., 1999; Wei et al., 1996). 
uPAR not only functions as a receptor for uPA, but is also involved in the 
regulation of cell migration, adhesion, differentiation, and proliferation. This 
occurs mainly through the specialized properties of the uPA/uPAR complex as a 
transducer of intracellular signaling. The signaling functions are mostly 
independent of the proteolytic activity of uPA, since catalytically inactive 
derivatives of uPA are as effective as active two-chain form in inducing 
intracellular signals. However, the binding of uPA to uPAR is required for these 
functions. Downstream targets of uPAR include protein kinases such as Src, FAK, 
and mitogen-activated protein kinase (Blasi and Carmeliet, 2002). 
Inhibitors of plasminogen activators 
There are three plasminogen activator inhibitors, PAI-1, PAI-2, and PAI-3, of 
which PAI-1 is thought to be physiologically the most important. PAI-1 is a 50 
kDA protein capable of inhibiting both uPA and tPA. PAI-1 is secreted by 
endothelial cells and is abundant in the blood (Ginsburg et al., 1986; Juhan-Vague 
et al., 1984). It is also secreted by other cell types, such as fibroblasts, smooth 
muscle cells, hepatocytes, adipocytes, as well as tumor cells (Feinberg et al., 
1989; Quax et al., 1990; Samad et al., 1996). 
The three dimensional structure of the uPA/PAI-1 complex has not been 
solved yet, but PAI-1 is known to bind uPA in a 1:1 stoichiometric ratio via a 20-
aa sequence motif termed the reactive center (Wind et al., 2002). Free PAI-1 is 
unstable, and is rapidly converted to a latent form with low inhibitory capacity. 
The binding of PAI-1 to vitronectin stabilizes the active conformation. PAI-1 in 
complex with uPA is not able to bind vitronectin (Seiffert et al., 1994). 
PAI-2 is expressed mainly in monocytes and placental cells (Feinberg et al., 
1989; Wohlwend et al., 1987). It also inhibits both uPA and tPA, but is less potent 
in its inhibition than PAI-1. High PAI-2 levels have been found in the sera of 
pregnant women, as well as in malignancy-associated ascites, which may 
contribute to the increased occurrence of thrombosis frequently associated with 
these conditions (Nilsson et al., 1986; Quax et al., 1990). 
PAI-3 (protein-C inhibitor) is expressed by colon and breast carcinoma cells, 
but its role in the regulation of plasminogen activation and thrombosis is still 
unclear (Costantini et al., 1991). 
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Interplay between proteolysis, signaling, and migration 
Cell migration is an important process in normal tissue morphogenesis and 
repair, but when deregulated, it is also a major contributor to numerous 
pathological conditions. Proteases are involved in cell migration via several 
different pathways. In response to chemoattractants, pericellular matrix is 
degraded by cell surface associated proteases to clear a path for the migrating cell. 
Recent studies have implicated, however, that this targeted proteolysis plays a 
subtler role in cell migration. Changes in cell shape and adhesion are required for 
cell motility. Proteases act in coordination with cell surface adhesion molecules 
and components of the ECM to reorganize the cytoskeleton and to regulate cell-
cell and cell-matrix interactions. In addition, cell surface associated proteases not 
only respond to, but also induce and regulate multiple intracellular signaling 
pathways. This regulation occurs through interactions with cell surface receptors 
and their intracellular partners (Blasi and Carmeliet, 2002; Stefansson and 
Lawrence, 2003). Proteases can also activate and release growth factors 
sequestered in the ECM, which subsequently promote cell migration (Lyons et al., 
1988; Saksela and Rifkin, 1990; Taipale and Keski-Oja, 1997). Limited 
proteolysis also exposes cryptic fragments in the ECM that locally regulate cell 
behavior (Giannelli et al., 1997; Xu et al., 2001). The uPA/PAI-1/uPAR system 
plays an important role in cell migration. Expression of uPAR has been linked to 
cell migration important to inflammation and tumor metastasis (Andreasen et al., 
2000; Bianchi et al., 1996; Huang et al., 2000). 
The effects of uPAR on cell migration are mediated via its interactions with 
several transmembrane proteins, which include integrins, GPCRs, and caveolin-1. 
Ligand-activated uPAR regulates integrin-dependent cell migration and adhesion 
via direct association with the α subunit of integrins (Fig. 3). The fibronectin 
receptor α5β1 integrin and the laminin receptor α3β1 integrin seem to bind uPAR 
with the highest affinity (Bohuslav et al., 1995; Simon et al., 2000; Wei et al., 
2001; Wei et al., 1996; Yebra et al., 1996). Inhibition of the interaction of uPAR 
with integrins leads to the inhibition of integrin-mediated cell spreading and 
migration via inhibition of the downstream tyrosine kinases FAK and Src 
(Aguirre Ghiso et al., 1999; Wei et al., 2001). 
Gradients of uPA and pro-uPA are also chemotactic for cells expressing 
uPAR. Binding of uPA to uPAR induces unmasking of a chemotactic epitope 
between domains D1 and D2 of the receptor. This epitope can also be exposed via 
direct proteolytic shedding of the D2D3 fragment (Fazioli et al., 1997; Resnati et 
al., 1996). The chemotactic effect is transduced via a GPCR, which binds the 
cryptic epitope and acts as a transmembrane adaptor (Fig. 3)(Resnati et al., 2002). 
The subcellular localization of uPAR is critical in determining its 
transmembrane binding partners and subsequent cellular functions. uPAR 
interacts directly with caveolin-1, a scaffold protein that through its cholesterol 
binding properties and propensity to oligomerize regulates the formation of 
membrane microdomains termed caveolae (Simons and Ikonen, 1997; Wei et al., 
1999). The localization of uPAR into lipid rafts is essential for its ability to bind 
vitronectin (Cunningham et al., 2003). On the other hand, uPAR can be localized 
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to the leading edge of migrating cells, where it associates with focal adhesions and 
regulates targeted proteolysis, cell-matrix interactions, and cytoskeletal 
rearrangement (Degryse et al., 1999; Gomez-Mouton et al., 2001; Kroon et al., 
1999; Myöhänen et al., 1993). 
Figure 3. uPAR regulates pericellular proteolysis, cell adhesion and chemotaxis. A. uPAR 
localizes the proteolytic activity of uPA to the pericellular area. PAI-1 binds uPAR-bound uPA on 
the cell surface and inhibits its proteolytic activity. B. uPAR binds vitronectin via an interaction 
dependent on uPA and modulates cell adhesion. In addition, uPAR directly interacts with 
integrins, mediates their affinity to ECM ligands and induces intracellular signaling. C. Binding of 
uPA to uPAR unmasks a chemotactic epitope between domains D1 and D2 of the receptor. The 
epitope can also be exposed by proteolytic shedding of the D2D3 fragment. The chemotactic 
effects are mediated via G-protein-coupled receptors (GPCR), which bind the cryptic epitope. 
PAI-1 affects cell behavior via multiple mechanisms. Direct inhibition of 
plasminogen activation by PAI-1 results in decreased pericellular proteolysis with 
subsequent effects on cell adhesion and migration. Binding of PAI-1 to uPAR-
bound uPA induces internalization of the complex, which affects the turnover and 
recycling of uPAR. Via its effect on uPA/uPAR internalization PAI-1 can also 
affect uPAR-mediated signaling. PAI-1-mediated endocytosis has been observed 
to enhance the phosphorylation of ERK induced by uPAR (Webb et al., 2001). In 
addition, PAI-1 is capable of inhibiting the interactions of both uPAR and 
integrins with vitronectin, and can induce the detachment of cells adhering to 
vitronectin (Stefansson and Lawrence, 1996). On the other hand it promotes α5β1
integrin-mediated migration from vitronectin toward fibronectin (Isogai et al., 
2001). The effects of PAI-1 are highly concentration dependent. It promotes cell 
migration by reducing the amount of cell adhesion sites, but the saturation of these 
sites effectively prevents migration by complete inhibition of cell attachment 
(Loskutoff et al., 1999). Addition of uPA to this system decreases the affinity of 
PAI-1 to vitronectin (Seiffert et al., 1994). Thus, uPA could indirectly promote 
cell migration by removing of PAI-1 from the matrix, which leads to the exposure 
of integrin binding sites in the ECM. 
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Vasculogenesis and angiogenesis 
The first functional organ system in mammalian embryonic development is 
the circulatory system. Mammalian cells require oxygen and nutrients for their 
survival, and the circulatory system functions in the delivery of these substances 
as well as in the removal of waste products. Blood vessel formation in the 
developing organism involves endothelial cell precursors, which assemble into a 
primitive vascular plexus of veins and arteries in response to growth factor 
stimulus. This process is termed vasculogenesis. This primitive vascular network 
is further remodeled and expanded by sprouting, vessel splitting, and fusion to 
form the mature vascular network in a process collectively termed angiogenesis. 
Finally, depending on the specialized function and host tissue of the vessels, the 
endothelial cells variably recruit pericytes and smooth muscle cells to form the 
periendothelial cell layer. Extracellular matrix is also produced to form the 
vascular BM, which stabilizes the vessel structures. In the adult, new vessels are 
produced mainly through angiogenesis, which occurs in conditions like tissue 
regeneration, inflammation, and cancer (Carmeliet, 2000; Klagsbrun and 
D'Amore, 1991; Risau, 1997). 
Molecular mechanisms of angiogenesis 
Mammalian cells must be located within the diffusion limit for oxygen (100 
to 200 µm) of blood vessels to survive. Growth of a tissue beyond this limit leads 
to hypoxia. Under hypoxic conditions a transcriptional complex composed of 
hypoxia inducible factors is stabilized, leading to transcription of hypoxia 
inducible genes. These genes commonly encode for angiogenic growth factors 
such as vascular endothelial growth factor (VEGF) and angiopoietin-2 (Semenza, 
2001). VEGF promotes vascular permeability and angiopoietin-2 loosens 
endothelial cell-matrix interactions, which are initial steps in angiogenic 
sprouting. This is followed by the release of proteases to degrade the surrounding 
ECM and extravasation of plasma proteins. These events facilitate endothelial cell 
migration by removing tissue boundaries, by liberating additional matrix-bound 
growth factors, and by providing a provisional matrix for cell attachment. Other 
important growth factors involved in the stimulation of endothelial cell migration 
include basic fibroblast growth factor (bFGF) and platelet derived growth factor 
(PDGF) (Conway et al., 2001; Ferrara, 2002; Yancopoulos et al., 2000). 
The migrating endothelial cells subsequently adhere to the surrounding ECM, 
form tubular structures, and acquire a lumen. These processes are regulated by 
synergistic activity of various growth factors as well as integrin-mediated 
signaling and modulation of cell-matrix interactions (Bayless et al., 2000; 
Koolwijk et al., 1996). Finally, the vessel structures are stabilized and the 
endothelial cells acquire a quiescent phenotype (Fig. 4). Vascular integrity is 
maintained through survival signals generated by growth factors and shear stress 
(Carmeliet, 2000). 
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Figure 4. Cellular events in angiogenesis. Tumor cells, immune cells and stromal fibroblasts 
secrete growth factors and proteases, which induce degradation of the vascular BM and formation 
of the provisional matrix. These changes promote the proliferation and migration of endothelial 
cells. The migrating endothelial cells adhere to the surrounding ECM, form tubular structures, 
and acquire a lumen. The vessel structures are stabilized by the formation of the mature BM and 
the recruitment of pericytes. Fragments of the degraded BM are important regulators of these 
processes. Modified from (Kalluri, 2003). 
Tumor angiogenesis and the angiogenic switch 
An expanding tumor becomes rapidly hypoxic and undergoes necrotic cell 
death unless it becomes capable of developing its own vasculature. Tumor vessels 
develop by sprouting or splitting from pre-existing vessels (Carmeliet and Jain, 
2000). In addition, recruited circulating endothelial cell precursors or stem cells 
mobilized directly from the bone marrow may contribute to the process (Rafii et 
al., 2002). Tumor vessels are abnormal in both structure and function. They are 
tortuous and dilated, with excessive branching and high permeability. In addition, 
the tumor endothelial cells often lack the perivascular cell lining, resulting in the 
lack of stability of the vessels. The tumor vessel wall is often a mosaic of 
endothelial cells and cancer cells, or it can lack endothelial cells entirely (Chang 
et al., 2000). The abnormal conditions result in variable blood flow and transient 
hypoxic events, which subsequently affect the production of angiogenic growth 
factors, promote the selection of cancer cell clones more resistant to hypoxia, and 
lower effectiveness of anti-cancer therapy (Eberhard et al., 2000). 
The ability of tumors to induce angiogenesis is acquired in a stepwise process 
described as an angiogenic switch. Analysis of various transgenic mouse models 
has revealed that oncogene expression and hyperproliferation are not sufficient to 
transform a carcinoma in situ-lesion into an expanding tumor. Instead, 
accumulating evidence suggests that the rate-limiting step of tumorigenesis is the 
ability of the lesions to acquire an angiogenetic phenotype. This occurs through a 
shift in the balance of pro- and anti-angiogenic agents, which can be derived from 
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cancer cells, endothelial cells, or stromal cells (Hanahan and Folkman, 1996). 
Several tumors express increased levels of VEGF and/or bFGF, and decreased 
levels of endogenous inhibitors of angiogenesis, such as thrombospondin-1. These 
changes in expression levels may be a consequence of mutations in oncogenes or 
tumor suppressor genes (Rak et al., 2002). Another source of pro-angiogenic 
factors are inflammatory cells infiltrating the tumor, which secrete VEGF, 
angiopoietin-1, bFGF, PDGF, and many others (Yu and Rak, 2003). In addition, 
enhanced secretion of proteases leads to increased bioavailability of angiogenic 
growth factors through their release from the ECM (Bergers and Benjamin, 2003; 
Taipale and Keski-Oja, 1997). On the other hand, excess proteolysis may also 
contribute to the generation of anti-angiogenic molecules by exposing cryptic 
fragments of matrix molecules (Kalluri, 2003). 
Role of integrins in angiogenesis 
Endothelial cells express multiple integrins, but endothelial cell integrins 
αvβ3, αvβ5, and α5β1 are considered central to the regulation of angiogenesis. 
Integrins αvβ3 and αvβ5 become dramatically induced in activated endothelial cells 
in the tumor vasculature. In addition, inhibitors of integrins αvβ3, and αvβ5 disrupt 
pathological angiogenesis in various model systems (Brooks et al., 1994a; Brooks 
et al., 1994b; Hammes et al., 1996). However, mice lacking β3 integrins have no 
defects in developmental angiogenesis, but instead display enhanced tumor 
angiogenesis (Reynolds et al., 2002), suggesting that β3 integrins can also function 
as negative regulators of angiogenesis (Hynes, 2002b). A putative mechanism of 
negative regulation via αvβ3 integrin is its interaction with endogenous 
angiogenesis inhibitors such as tumstatin (Hamano et al., 2003; Maeshima et al., 
2002). In addition, negative regulation could be mediated via integrinmediated 
cell death, where expression of αvβ3 integrin in the absence of proper ligands 
results in endothelial cell apoptosis (Stupack et al., 2001). Furthermore, extensive 
crosstalk occurs between different integrin heterodimers, suggesting that they 
could functionally substitute for each other during angiogenesis (Hynes, 2002b; 
Kim et al., 2000b; Simon et al., 1997). 
The role of integrin α5β1 seems to be different from that of the αv integrins. 
Like αv integrins, α5β1 integrin is upregulated on endothelial cells in response to 
angiogenic growth factors (Kim et al., 2000a). In contrast to αv integrins, the loss 
of α5 leads to severely impaired developmental angiogenesis (Yang et al., 1993). 
In addition, neutralization of the function of this integrin by specific antibodies or 
synthetic peptides inhibits bFGF-induced angiogenesis in vitro and in vivo (Kim 
et al., 2000a). 
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Proteolytic cascades in angiogenesis 
Proteases are involved in multiple aspects of angiogenesis. Proteolyic 
degradation of sub-endothelial BM is required for endothelial cell migration into 
the underlying ECM. In addition, proteases stimulate endothelial cell migration 
through activation of pro-angiogenic growth factors and through their release 
from the ECM. In addition, proteolytic cleavage of the ECM unmasks cryptic 
adhesion sites and liberates bioactive degradation products (Pepper et al., 1996; 
Werb et al., 1999). On the other hand, proteases negatively regulate angiogenesis 
by generation of endogenous inhibitors of angiogenesis from the components of 
the ECM (Kalluri, 2003). Physiological angiogenesis requires a balance in 
proteolysis. Excessive proteolysis results in inhibition of angiogenesis due to 
destruction of the matrix scaffold that is needed for endothelial cell migration and 
tubular morphogenesis and generation of endogenous inhibitors of angiogenesis. 
Insufficient proteolysis, on the other hand, inhibits migration and tubular 
morphogenesis due to limited degradation of ECM barriers and release of 
proangiogenic growth factors (Bergers and Benjamin, 2003; Pepper, 2001). The 
most relevant protease systems involved in angiogenesis are the plasminogen 
activators and the MMPs. 
uPA, uPAR, and PAI-1 are not detectable in the quiescent endothelium, but 
are expressed during active angiogenesis (Bacharach et al., 1992; Larsson et al., 
1984). In vitro, the expression of these proteins is regulated by angiogenic growth 
factors such as bFGF and VEGF (Mignatti and Rifkin, 1996). In addition, at least 
uPAR and PAI-1 are upregulated by hypoxia, a major inducer of angiogenesis 
(Kroon et al., 2000; Uchiyama et al., 2000). uPA induces neovascularization in the 
rabbit cornea and promotes growth, chemotaxis, and matrix invasion of cultured 
endothelial cells. These effects require interaction of uPA with uPAR, which can 
be prevented by monoclonal antibodies against either of the proteins (Fibbi et al., 
1998). Despite the evidence implicating a role for the plasminogen activator 
system in angiogenesis, no abnormalities in vascular development are seen in 
mice lacking uPA, tPA, or uPAR (Carmeliet et al., 1994; Dewerchin et al., 1996). 
Several studies have, however, indicated a role for plasminogen activators in other 
processes involving angiogenesis. The uPA/uPAR interaction has been observed 
to be important for tumor-associated neovascularization, primary tumor growth, 
and metastasis (Crowley et al., 1993; Min et al., 1996; Ossowski, 1996). Studies 
on PAI-1 deficient mice have revealed it to be crucial for tumor vascularization, 
and that the proteolytic activity of plasmin is involved in this process. The role of 
PAI-1 is to maintain controlled proteolytic breakdown of the ECM (Bajou et al., 
2001; Bajou et al., 1998). tPA is important for the maintenance of vascular 
patency in uninjured arteries, but does not seem to play an important role in 
angiogenesis (Loskutoff et al., 1995). 
Endothelial cells express MMP-1, -2, -3, -9, and 14. The basal expression 
levels of these proteases are relatively low, but they are upregulated in a variety of 
physiological and pathological conditions involving neovessel formation. These 
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include embryogenesis, wound healing, rheumatoid arthritis, and cancer (John and 
Tuszynski, 2001; Pepper, 2001). MMP-9 is upregulated in angiogenic lesions, and 
in a transgenic mouse model of pancreatic islet carcinomas, it has been shown to 
induce the transition of benign carcinoma in situ lesions into angiogenic 
carcinomas, via an increase in the bioavailabilty of vascular endothelial growth 
factor VEGF (Bergers et al., 2000). On the other hand, MMP-9 is essential in 
generating the anti-angiogenic fragment tumstatin from type IV collagen. When 
tumor growth exceeds a critical size, accelerated tumor growth is observed in 
mice lacking MMP-9 (Hamano et al., 2003). MMP-2 has been observed to play a 
role in angiogenesis in a rat Swarm chondrosarcoma model, in which increased 
MMP-2 activity was associated with the switch to the angiogenic phenotype 
(Fang et al., 2000). In addition, the C-terminal hemopexin-like domain of MMP-2 
inhibits bFGF induced angiogenesis and tumor growth. It also inhibits the 
targeting of MMP-2 to the cell surface via αvβ3 integrin (Brooks et al., 1998; 
Silletti et al., 2001). MMP-2 deficient mice display reduced tumor angiogenesis in 
a dorsal sac assay with B16-BL6 melanoma cells (Itoh et al., 1998). MT1-MMP is 
expressed at high levels in the endothelium of the developing embryo (Apte et al., 
1997). MT1-MMP deficient mice display defects in angiogenesis in the cartilage. 
In addition, an impaired angiogenic response to bFGF stimulus is seen in the 
corneal angiogenesis assay of these mice (Holmbeck et al., 1999; Zhou et al., 
2000). Analysis of the fibrinolytic activity in an ex vivo model has revealed MT1-
MMP to be an extremely potent fibrinolytic enzyme, suggesting an important role 
for this protease in endothelial cell invasion of the provisional ECM (Hiraoka et 
al., 1998). In addition, the ability of MT1-MMP to activate MMP-2 may provide 
additional roles for this enzyme in angiogenesis.  
Basement membrane-derived inhibitors of angiogenesis 
Vascular integrity and endothelial cell quiescence is maintained in part via 
interaction of endothelial cells with the underlying intact basement membrane. 
However, as a result of angiogenesis-associated assembly or disassembly of the 
BM, endothelial cells interact with the different domains of these proteins. Thus, 
the same molecules, depending on their structural configuration, differently 
regulate endothelial cell behavior at various stages of the angiogenic process and 
cancer progression. As the angiogenic switch is turned on, targeted proteolysis 
induces degradation of the BM, and cryptic domains of partially degraded 
collagens become exposed. Fragments of perlecan, laminin, SPARC, type XV 
collagen and type XVIII collagen are molecules, which contain both anti- and pro-
angiogenic cues (Mongiat et al., 2003; Ortega and Werb, 2002; Sage et al., 2003). 
Fragments of type IV collagen 
Type IV collagen isolated from the vascular BM contains no anti-angiogenic 
activity. However, when the collagen is further degraded with a mixture of tumor 
microenvironment-associated proteolytic enzymes, the liberated cryptic fragments 
have anti-angiogenic activity (Petitclerc et al., 2000). Three of the fragments 
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derived from the α1, α2, and α3 chains of the NC1 domain of type collagen IV 
have been named arrestin, canstatin, and tumstatin, respectively (see Table 1) 
(Colorado et al., 2000; Kamphaus et al., 2000; Maeshima et al., 2002). The 
divergent functions of the degradation products are probably consequences of the 
altered integrin usage of these fragments. Intact type IV collagen promotes 
endothelial cell proliferation and migration through interactions with integrins 
α1β1 and α2β1. However, proteolytic degradation of collagen IV leads to 
decreased binding to these integrins. Instead, tumstatin binds αvβ3 and α6β1,
canstatin binds αvβ3 and α3β1, and arrestin binds α1β1. Binding of these fragments 
to integrins is likely to mediate their anti-angiogenic activity (Kerbel and 
Folkman, 2002; Petitclerc et al., 2000). 
Table 1. Basement membrane-derived inhibitors of angiogenesis 
Abbreviations: NA, not analyzed. Modified from (Kalluri, 2003). 
Tumstatin inhibits the proliferation of endothelial cells and blood vessel 
formation in vitro and in vivo. It also inhibits tumor angiogenesis and suppresses 
tumor growth in various animal models (Maeshima et al., 2000a; Maeshima et al., 
2000b; Maeshima et al., 2001a; Maeshima et al., 2001b; Maeshima et al., 2002) 
Tumstatin acts through αvβ3-dependent inhibition of cap-dependent protein 
synthesis. This occurs through Phosphatidyl-3 kinase and Akt-mediated inhibition 
of mTOR, an important activator of cap-dependent translation (Maeshima et al., 
2002). Tumstatin binds to αvβ3 integrin via a mechanism independent of the 
RGD-sequence. Its biological activity has been localized to a 25 aa stretch in the 
middle of the molecule (Maeshima et al., 2001b). 
Tumstatin is present in the plasma of healthy human individuals as well as 




















α1 chain of 
type XVIII 
collagen
No Yes Yes α5β1 integrin
Human 
endostatin-like
α1 chain of 
type XV 
collagen
Yes Yes NA NA
Arrestin 
α1 chain of 
type IV 
collagen
Yes Yes Yes α1β1 integrin
Canstatin 
α2 chain of 
type IV 
collagen
Yes Yes Yes NA
Tumstatin 
α3 chain of 
type IV 
collagen
Yes No Yes αvβ3 integrin
α6(IV)NC1 
domain
α6 chain of 
type IV 
collagen
Yes NA NA NA
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mediated proteolysis as part of the regular turnover process of BMs (Kalluri, 
2003). Studies on mice lacking the α3 chain of collagen IV/tumstatin suggest, that 
the physiological levels of circulating tumstatin suppress tumor angiogenesis 
through interaction with the αvβ3 integrin expressed in the tumor endothelium. 
Physiological processes involving angiogenesis, such as pregnancy, development, 
and wound healing occur normally in these mice. MMP-9 deficient mice have 
reduced levels of circulating tumstatin, and display accelerated tumor growth after 
the tumors exceed 500 mm3 in size. Tumor growth can be sustained with the 
delivery of exogenous tumstatin (Hamano et al., 2003). 
Endostatin 
Endostatin was isolated in 1996 from the conditioned media of a murine 
hemangioendothelioma (EOMA) cell line. Sequence analysis revealed it to be the 
C-terminal, 20 kDa fragment of the NC1 domain of type XVIII collagen. In the 
pioneer study, soluble baculovirally produced endostatin was observed to be an 
endothelial cell-specific inhibitor of endothelial cell proliferation and migration 
(O'Reilly et al., 1997). The growth of primary tumors, such as the Lewis lung 
carcinoma, T241 fibrosarcoma, EOMA hemangioendothelioma and B16F10 
melanoma planted in syngeneic mice, were inhibited by systemic administration 
of endostatin, produced as an insoluble precipitate in E. coli. No evidence of any 
toxicity, drug resistance, or regrowth of tumors during treatment was observed 
(O'Reilly et al., 1997). 
Structural features 
Endostatin is cleaved C-terminally of the trimerization domain of type XVIII 
collagen to yield monomeric endostatin. The cleavage can be executed by various 
proteinases, including cysteine proteinases such as cathepsin L, MMPs, and the 
serine proteinase elastase. Proteolytic processing of type XVIII collagen generates 
both NC1 trimers and endostatin monomers in vivo, and both forms can be 
detected in tissues and serum. MMPs generate a 30-kDa fragment, but cathepsin L 
directly releases the 20-kDa endostatin fragment. Endostatin itself is resistant to 
proteolysis by MMPs, but is degraded by the other proteinases. Protease activity 
thus regulates both the generation and stability of endostatin (Felbor et al., 2000; 
Ferreras et al., 2000; Sasaki et al., 1998; Wen et al., 1999). Proteolytically cleaved 
endostatin remains associated with the vascular BM, where it colocalizes with the 
heparan sulfate proteoglycan perlecan (Miosge et al., 1999). Endostatin has also 
been detected from platelets and the plasma of healthy individuals (Ma et al., 
2001; Zorick et al., 2001). 
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Figure 5. Model of the three dimensional structure of the mouse collagen XVIII C-terminal 
domain, endostatin. The endostatin domain has a compact globular fold that is distantly related to 
the C-type lectins. The four cysteines of endostatin are linked 14, 23. A zinc ion is bound near 
the N-terminus, but the zinc binding site appears not to be functionally important. Endostatin 
contains an arginine rich extensive basic patch responsible for its binding to heparan sulfate. The 
basic arginine (R) residues and the solvent-exposed side chains of phenylalanine (F) residues are 
labeled (Hohenester and Engel, 2002; Hohenester et al., 1998). 
The structure of the endostatin domain is related to the C-type lectin 
carbohydrate-recognition domain (Fig. 5). It is characterized by a compact 
globular fold and a basic patch of 11 arginine residues, which act as binding sites 
for heparin (Hohenester et al., 1998; Kreuger et al., 2002). Endostatin binds also 
Zn++ at a 1:1 molar ratio, but this property does not seem to be essential for the 
activity of endostatin (Ding et al., 1998; Hohenester et al., 2000; Yamaguchi et al., 
1999). The molecule is stabilized by two intramolecular disulfide bridges 
(Standker et al., 1997). 
The NC1 domain of type XV collagen is highly homologous to that of type 
XVIII with 60 % sequence identity. Its proteolytic fragment has also been 
observed to have anti-angiogenic activity, although it is less potent than 
endostatin. Interestingly, the fragment of type XV collagen, termed restin or 
endostatin-like, lacks the zinc- and heparin-binding domains (Sasaki et al., 2002). 
Biological roles 
The basement membrane location of the endostatin fragment suggests a local 
regulatory role of endostatin in vessel growth. However, endostatin appears not to 
be a critical regulator of angiogenesis, since type XVIII collagen/endostatin-
deficient mice display no major vascular abnormalities. No significant changes in 
the growth of primary tumors or tumor angiogenesis compared to the wild-type 
mice have been observed (Fukai et al., 2002). In addition, patients with Knobloch 
syndrome do not display vascular abnormalities or increased incidence of cancer 
(Sertie et al., 2000). 
The physiological levels of circulating endostatin in the plasma of healthy 
individuals ranges from 10-50 ng/ml (0.5-2.5 nM), with a wide range of variation 
within the population (Hefler et al., 1999; Zorick et al., 2001). The biological 
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functions of circulating endostatin are currently unclear. It might participate in the 
regulation of angiogenesis, but the circulating concentrations are lower than those 
that efficiently inhibit endothelial cell migration in vitro. A number of studies 
have reported elevated levels of circulating endostatin in various types of human 
cancer. The elevated levels of endostatin correlate to tumor aggressiveness and 
poor prognosis (Feldman et al., 2000b; Feldman et al., 2001b; Feldman et al., 
2001c; Feldman et al., 2002; Shaarawy and El-Sharkawy, 2001; Suzuki et al., 
2002). Interestingly, a point mutation in endostatin has been reported to 
predispose to the development of prostate adenocarcinoma (Iughetti et al., 2001). 
Down syndrome is a complex developmental disorder most commonly 
caused by a duplication of one of the copies of chromosome 21, which is the 
chromosome where the COL18A1 gene is located. Down syndrome patients have 
decreased incidence for solid tumors and concomitantly increased serum levels of 
endostatin. No recognized tumor suppressor genes localize to this chromosome, 
implying that circulating endostatin might act as a protective agent for the 
development of solid tumors (Zorick et al., 2001). 
Studies on cle-1, the Caenorhabditis elegans homologue of type XVIII 
collagen, have revealed a putative role for the NC1 domain/endostatin in cell 
motility. The protein is expressed at high levels in the nervous system, and 
deletion of the domain leads to multiple defects in axon guidance and migration of 
neural and non-neural cells. Interestingly, this phenotype can be rescued by 
ectopic expression of the trimeric NC1, but not monomeric endostatin (Ackley et 
al., 2001). The motogenic activity of the trimeric NC1 domain of human type 
XVIII collagen and its inhibition by monomeric endostatin is also observed cell 
culture experiments. The activity of the NC1 domain is not specific for endothelial 
cells, but has also been observed with various non-endothelial cells, whereas the 
activity of endostatin is restricted to endothelial cells. The motogenic activity of 
NC1 is dependent on the presence of the ECM and of rac, cdc42 and the MAP 
kinase pathway (Kuo et al., 2001). 
Endostatin may also regulate tissue morphogenesis. The ureteric bud 
produces the endostatin fragment, which inhibits hepatocyte growth factor-
induced migration and branching morphogenesis of renal epithelial cells and the 
ureteric bud. These effects are dependent on the presence of the heparan sulfate 
proteoglycan syndecan-3 (Karihaloo et al., 2001). 
Effects of endostatin on tumor growth 
While the biological role of the endostatin fragment is still unclear, numerous 
studies have indicated recombinant endostatin to be a very potent inhibitor of 
tumor angiogenesis. The lack of dramatic vascular effects of endogenous 
endostatin could be a result of its sequestration in the basement membranes, where 
it is not accessible for interaction with cell surface receptors (Fukai et al., 2002). 
In addition, the concentrations of endostatin used to achieve anti-tumor effects are 
10-fold higher than the levels of endostatin in the circulation, suggesting that the 
pharmacological effects of high concentrations of endostatin might be distinct 
from its physiological effects. 
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Table 2. Anti-tumor effects of endostatin in animal models.
Abbreviations: s.c. , subcutaneous; i.m., intramuscular; i.p., intraperitoneal 
Animal Tumor type Administration Effect Reference






Inhibition of tumor growth (O'Reilly et 
al., 1997) 






Tumor dormancy after repeated 
cycles of treatment 
(Boehm et 
al., 1997) 
Mouse BALB/c renal cell 
carcinoma, 








Mouse RIP1-Tag2 transgenic 





Inhibition of angiogenic switch, 
regression of tumors 
(Bergers et 
al., 1999) 
Mouse Mouse renal cell 
carcinoma, 





Inhibition of metastasis (Yoon et al., 
1999) 
Mouse MC38 adenocarcinoma Adenoviral 
delivery of 
endostatin gene 
Inhibition of tumor growth (Feldman et 
al., 2000a) 
Mouse JC breast carcinoma, 




Inhibition of tumor growth, 
inhibition of metastasis







Inhibition of tumor growth (Perletti et 
al., 2000) 






Delayed tumor development, 
decreased tumor burden 
(Yokoyama 
et al., 2000) 




Regression of tumor, increased 
survival 
(Read et al., 
2001) 






Regression of tumor (Joki et al., 
2001) 





Inhibition of tumor growth (Ding et al., 
2001) 









Mouse BxPC-3 pancreatic 
carcinoma, 
HT-1080 fibrosarcoma, 





Inhibition of tumor growth, 
continuous infusion increases 




Studies on various animal models have shown that endostatin inhibits the 
growth of primary tumors. In addition, endostatin can inhibit or reduce the 
formation of metastases (Table 2). Strikingly, when delivered in cycles where the 
tumors are allowed to regrow between repeated treatments, endostatin is still 
effective and induces prolonged tumor dormancy without drug resistance (Boehm 
et al., 1997). 
In the adult, endostatin seems to specifically act on tumor vessels. 
Physiological processes involving angiogenesis, such as wound healing are 
essentially unaffected by endostatin treatment, even though some disturbances in 
vessel maturation can be seen (Berger et al., 2000; Bloch et al., 2000). This might 
be a result of altered expression of cell surface proteins in tumor blood vessels 
compared to the normal vasculature (Ruoslahti, 2002). Endostatin may also target 
endothelial cell progenitors, and inhibit their mobilization and clonogenic 
potential. Endothelial cell progenitors play a role in tumor angiogenesis at least in 
certain tumor types (Capillo et al., 2003; Schuch et al., 2003). 
Cell surface receptors 
A number of different putative cell surface receptors for endostatin have been 
identified. Immobilized endostatin promotes cell adhesion via α5β1 and αvβ3
integrins (Rehn et al., 2001). Soluble endostatin has been observed to inhibit α5β1-
mediated signaling. In addition, blocking the interaction between endostatin and 
integrin α5β1 leads to the loss of endostatin-induced effects on cell migration, 
indicating that α5β1 integrin is a functional receptor for endostatin (Sudhakar et 
al., 2003). However, both mouse and human endostatin lack RGD-sequences, and 
specific integrin-binding sites have not been identified yet. 
Endostatin is also a heparin-binding protein. Studies using chick 
chorioallantoic membrane assay as a model for growth factor induced 
angiogenesis indicate that mutations of arginine residues critical for heparin 
binding results in the loss of endostatin function (Sasaki et al., 1999). In addition, 
endostatin binds with low affinity to glypicans 1 and 4, cell surface heparan 
sulfate proteoglycans expressed on endothelial cells (Karumanchi et al., 2001). 
The recognition motif of endostatin on glycosaminoglycans is highly specific and 
distinct from known growth factor binding domains, providing a putative 
explanation for the preferential interaction of endostatin with specific cell surface 
proteoglycan species (Kreuger et al., 2002). 
Endostatin has also been reported to bind to VEGF receptor 2, resulting in 
competitive inhibition of receptor activity (Kim et al., 2002). Other studies have, 
however, concluded that endostatin does not interfere with major growth factor 
signaling pathways (Dixelius et al., 2000; Eriksson et al., 2003; Karihaloo et al., 
2001).
An intracellular actin-interacting protein tropomyosin has been identified as 
an endostatin binding protein by using a yeast two-hybrid approach. A peptide 
that inhibited the interaction between endostatin and tropomyosin-3 decreased the 
inhibitory effect of endostatin on the formation of metastases in a mouse 
melanoma model (MacDonald et al., 2001). 
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Mechanisms of action 
The possible cell biological mechanisms underlying the anti-angiogenic 
effects of endostatin include inhibition of endothelial cell migration, induction of 
cell cycle arrest, and promotion of apoptosis (Dhanabal et al., 1999; Dixelius et 
al., 2000; Hanai et al., 2002a; O'Reilly et al., 1997). The most consistent effects 
seem to be the inhibition of migration and proliferation. However, in contrast to 
mouse endostatin, human endostatin does not seem to affect endothelial cell 
proliferation (Sudhakar et al., 2003; Yamaguchi et al., 1999). The reason for this 
major difference in activity is unclear. Endostatin seems to act differently 
depending on the cell culture conditions. Endostatin induces apoptosis and 
inhibits cell migration in the absence of serum, but in the presence of serum only 
inhibition of migration is observed (Shichiri and Hirata, 2001). 
Endostatin inhibits bFGF in VEGF induced migration in several different 
endothelial cell types in vitro (Dhanabal et al., 1999; Dixelius et al., 2000; 
O'Reilly et al., 1997; Taddei et al., 1999; Yamaguchi et al., 1999), but the 
molecular targets of endostatin have remained unclear. Endostatin has various 
effects on intracellular signaling pathways in different types of endothelial cells. 
However, although endostatin is a potent inhibitor of bFGF- and VEGF-induced 
endothelial cell migration, it does not seem to affect the key signaling pathways 
involved in growth factor stimulated cell migration (Eriksson et al., 2003). 
Migration of endothelial cells involves concerted assembly and disassembly of 
focal adhesions in cooperation with integrin signaling. Immobilized endostatin 
promotes and soluble endostatin inhibits α5β1 integrin-mediated endothelial cell 
migration (Rehn et al., 2001; Sudhakar et al., 2003). In addition, endostatin targets 
the cytoskeleton by binding tropomyosin or affecting the assembly of the 
cytoskeleton (Dixelius et al., 2002; MacDonald et al., 2001). It also affects the 
stability and sub-cellular localization of β-catenin, a protein involved in the 
regulation of cell-cell interactions and cell motility (Dixelius et al., 2002). ß-
catenin has also been identified as a target for endostatin in studies using Xenopus
embryogenesis as a model for endostatin signaling. Endostatin RNA blocks the 
axis duplication induced by ß-catenin, partially inhibits Wnt-dependent 
transcription, and stimulates degradation of ß-catenin (Hanai et al., 2002b). 
Inhibition of VEGF-induced migration induces dephosphorylation of eNOS via an 
Akt-mediated pathway (Urbich et al., 2002). 
In addition to its anti-migratory effect, endostatin can act as a proteinase 
inhibitor. Endostatin inhibits MMP-2 activity by binding to its catalytic domain. 
The affinity of endostatin binding to MMP-2 is significantly weaker than that of 
the endogenous inhibitor tissue inhibitor of metalloproteinases (TIMP)-2 (Kim et 
al., 2000c; Lee et al., 2002). Inhibition of the activity of MMPs -9 and -13 has 
also been observed (Nyberg et al., 2003). 
The other putative cell biological effects of endostatin include induction of 
apoptosis via phosphorylation of the adaptor protein Shb (Dixelius et al., 2000), 
induction of endothelial cell cycle arrest (Hanai et al., 2002a), induction of 
intracellular calcium signaling (Jiang et al., 2001; Shichiri and Hirata, 2001), 
downregulation of genes involved in endothelial cell migration and proliferation 
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(Shichiri and Hirata, 2001; Yin et al., 2002), and induction of protein kinase A 
activity via cAMP production (Shichiri and Hirata, 2001). 
Angiogenesis inhibitors in cancer therapy 
Various inhibitors of angiogenesis have been developed to target vascular 
endothelial cells in order to inhibit tumor angiogenesis and thus prevent tumor 
growth. Targeting endothelial cells rather than the tumor cells themselves is 
promising, since endothelial cells are genetically stable and therefore less prone to 
accumulate mutations leading to drug resistance (Boehm et al., 1997). The 
mechanisms of action of angiogenesis inhibitors can be direct or indirect. Direct 
angiogenesis inhibitors such as endostatin and tumstatin target the tumor 
endothelial cells and inhibit their migration or proliferation (Table 3). Indirect 
angiogenesis inhibitors such as the receptor tyrosine kinase inhibitors target the 
tumor cells and inhibit the expression of pro-angiogenic proteins. They can also 
target the endothelial cells and inhibit the expression of the receptors for the pro-
angiogenic proteins (Kerbel and Folkman, 2002). 
Table 3. Direct inhibitors of angiogenesis. 
Drug Mechanisms of action Clinical trials Reference
Angiostatin Inhibits endothelial cell proliferation and migration Phase I
(O'Reilly et al., 
1994) 
Bevacizumab A humanized monoclonal antibody against VEGF Phase I and III (Ferrara, 2002) 
Arresten 
Binds to integrin α1β1 and inhibits 
endothelial cell proliferation and 
migration
No (Colorado et al., 2000) 
Canstatin 
Binds to integrin αvβ3 and inhibits 
endothelial cell proliferation and 
migration
Phase I (Kamphaus et al., 2000) 
Combretastatin Binds tubulin and causes microtubule depolymerization 
Completed 
Phase I
(Kanthou and Tozer, 
2002) 
Endostatin Binds integrin α5β1 and inhibits endothelial cell migration Phase I and II
(O'Reilly et al., 
1997) 
NM-3 Small molecule inhibitor of VEGF Phase I (Reimer et al., 2002) 
Thrombospondin 
Binds CD36 and inhibits 
endothelial cell proliferation and 
migration 
No (Lawler, 2000) 
Tumstatin Binds to integrin αvβ3 and inhibits endothelial cell proliferation No




Induces endothelial cell apoptosis 
by inhibiting microtubule function Phase I and II
(D'Amato et al., 
1994) 
Vitaxin A humanized monoclonal antibody against integrin αvβ3 Phase I and II (Gutheil et al., 2000) 
Modified from (Kerbel and Folkman, 2002). 
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Angiogenesis inhibitors exert their anti-tumor effects via multiple 
mechanisms. Most anti-angiogenic agents inhibit the sprouting of new 
microvessels from the existing vasculature, but also induce regression of recently 
developed microvessels. This subsequently leads to tumor cell death (Kieran et 
al., 2003). However, angiogenesis inhibitors also transiently decrease vessel 
leakiness, which results in increased tumor blood flow and decreased intratumor 
pressure. Angiogenesis inhibitors may thus enhance the efficacy of radiation 
therapy as well as increase the delivery of cytotoxic drugs into the tumors (Jain, 
2001). Despite an increase in blood flow in the early course of anti-angiogenic 
therapy, the net effect seems to be a gradual decrease in tumor blood flow. This 
effect has also been observed in endostatin-treated cancer patients (Herbst et al., 
2002b).
Studies on the effects of recombinant endostatin in various animal tumor 
models have indicated that continuous administration of endostatin is more 
efficient than interval or bolus treatment (Kisker et al., 2001). In addition, the anti-
angiogenic effects of endostatin are achieved most effectively by maintaining 
constant serum levels of 300-500 ng/ml, and concentrations below or above this 
window may result in decreased efficacy (Kerbel and Folkman, 2002). Several 
strategies for the constant and local delivery of endostatin have been successfully 
applied, including adenoviral gene transfer and implantation encapsulated 
endostatin producer cells (Feldman et al., 2001a; Joki et al., 2001; Read et al., 
2001; Sauter et al., 2000). 
The Phase I clinical trials of endostatin concluded that the recombinant 
protein can be administered to patients at high doses concentrations no signs of 
toxicity (Herbst et al., 2002a). Endostatin is currently in Phase II clinical trials, 
but the results are still unavailable. 
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Aims of the present study 
When this study was initiated, endostatin had been identified as an inhibitor of 
angiogenesis and tumor growth. The aims of the current study were to elucidate 
the cell biological mechanisms underlying the anti-angiogenic potential of 
endostatin and to understand the mechanisms by which a fragment of the ECM 
regulates cell-matrix interactions. As pericellular proteolysis is an important 
process in angiogenesis and endothelial cell migration, the first aim of this study 
was to analyze changes in endothelial cell plasminogen activation in response to 
endostatin treatment. During the course of these studies we found that endostatin 
induces the disruption of actin stress fibers and focal adhesions. This finding led 
us to further characterize the mechanisms by which endostatin associates with cell 
surface adhesion molecules and induces changes in cell adhesion and migration. 
Specific questions addressed in these studies include the following: 
1) How does endostatin regulate uPA and PAI-1 at the levels of protein 
expression, and how is their cell surface localization altered? 
2) How does endostatin affect the cytoskeletal structures involved in cell 
migration and what are the molecular mechanisms behind these effects? 
3) What kind of molecular interactions regulate the endothelial cell surface 
association of endostatin, and what are the consequences resulting from 
these interactions? 
4)  Which specific domains or amino acid sequences of the endostatin protein 
account for its cell surface and integrin binding properties? 
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Materials and methods
Cell culture and treatments 
Human dermal microvascular endothelial cells (HDMEC) were purchased 
from Promocell (Heidelberg, Germany) and were cultured in Endothelial Cell 
Growth Medium (Promocell), at 37 °C in a humidified 5 % CO2 atmosphere. The 
cells used for the experiments were from passages 3-6. All experiments were 
carried out under serum-free conditions, in which the cells were washed twice and 
incubated in serum-free medium-199 for at least 8 h prior to treatment with the 
various proteins or chemicals. The cells were treated with endostatin (40-50 nM), 
bFGF (50 ng/ml), PP1 (10-100 µM), orthovanadate (50-100 µM), heparinase III 
(20 mU/ml), Filipin III (2.5 µg/ml), methyl-β-cyclodextrin (5 mM) or endostatin-
derived peptides (500 nM) for various periods of time. 
Expression and characterization of human endostatin 
Recombinant human endostatin used in studies I and II was expressed and 
purified as described (Rehn et al., 2001). A fragment of human collagen XVIII 
that corresponds to mouse endostatin sequences (O'Reilly et al., 1997) was cloned 
to the vector pQE-31 (Qiagen, Inc., Santa Clarita, CA) and expressed as an N-
terminal His-tagged protein in E. coli strain M15 according to the manufacturers 
protocol (Qiagen). Bacterial pellets were lysed and the supernatant was lightly 
sonicated and applied to a ProBond column (Invitrogen, San Diego, CA). Bound 
protein was eluted by an imidazole gradient, and the endostatin fractions were 
pooled and refolded in vitro. Refolded soluble endostatin was separated by 
centrifugation and applied to a HiTrap SP cation-exchange column (Amersham 
Pharmacia, Piscataway, NJ). Endostatin fractions were eluted by a NaCl gradient 
and applied to a heparin-Sepharose CL-6B column (Amersham Pharmacia). 
Bound endostatin was eluted by a NaCl gradient. Endostatin fractions were pooled 
and dialyzed against PBS, pH 7.4, and passed through a Polymyxin agarose 
column using PBS buffer. No endotoxin was found in the purified fractions. In 
studies III and IV, endostatin was from Calbiochem. 
Growth factors, chemicals, and enzymes 
bFGF was from R&D Systems Inc. (Minneapolis, MN). Sodium 
orthovanadate was from Sigma Chemical Co. (St. Louis, MO). PP1 was 
purchased from Biomol Research Laboratories Inc. (Plymouth Meeting, PA). 
Human plasminogen was from Chromogenix (Mölndal, Sweden) and HMW-uPA 
from Calbiochem (San Diego, CA). 
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Antibodies 
The following antibodies have been used in the experiments as specified in 
the original publications. 
Name:  Source/ Clone:  Application:  Reference: 
α5 integrin Mouse / P1D6 BLK Chemicon 
αv integrin Mouse / M9 BLK Chemicon 
α5β1 integrin Mouse / JBS5 IF Chemicon 
α5β1 integrin Goat IB, IP Chemicon 
β1 integrin Mouse / P5D2 BLK Chemicon 
β3 integrin Rabbit BLK Chemicon 
Caveolin-1 Mouse IB Transduction 
Laboratories 
Caveolin-1 Rabbit IF, IP Transduction 
Laboratories 
Endostatin Rabbit IB Chemicon 
Fibronectin Rabbit IB, IF, IP Sigma 
Glypican-1 Mouse / N-16 IB Santa Cruz 
p190 Mouse / 30 IB, IP Transduction 
Laboratories 
PAI-1 Mouse IP American Diagnostica 
Paxillin Mouse IF Transduction 
Laboratories 
pSrc Rabbit IB, IF New England Biolabs 
RhoA Mouse IB Santa Cruz 
Src Rabbit IB, IP Santa Cruz 
Transferrin Receptor Mouse / 2 IB Transduction 
Laboratories 
uPA Rabbit IF, IP American Diagnostica 
uPAR Mouse IF (Rønne et al., 1991) 
Vinculin Mouse IF Sigma 
SDS-PAGE and immunoblotting 
SDS-PAGE (polyacrylamide gel electrophoresis in the presence of sodium 
dodecyl sulphate) was carried out using 4-15 % gradient polyacrylamide gels 
(Bio-Rad Co., Richmond, VA). The proteins were then transferred onto 
nitrocellulose filters, which were saturated with 5 % bovine serum albumin (BSA) 
in PBS/Tween-20 (0.05 %) to prevent non-specific binding. The filters were then 
incubated with primary antibodies in 50 mM Tris-HCl buffer, pH 8.5, containing 
500 mM NaCl, 0.05 % Tween-20, and 0.1 % bovine serum albumin. After 
extensive washing the bound antibodies were detected using biotinylated anti-
mouse and anti-rabbit antibodies, peroxidase-conjugated streptavidine and 
enhanced chemiluminescence detection system (Amersham). 
Casein zymography and reverse zymography 
Zymography and reverse zymography were used to identify the molecular 
forms of uPA and PAI (Granelli-Piperno and Reich, 1978). The polypeptides of 
the conditioned media or acid eluates were separated under non-reducing 
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conditions by SDS-PAGE (4-15 %). SDS was removed by washing the gels with 
PBS, pH 7.4 /Triton X-100 (2.5%) 4x15 min. For reverse zymography, reducing 
conditions were used and uPA (2 IU/ml) was added to the final wash. The gels 
were then placed on caseinolysis gels containing plasminogen and casein in 1.2% 
agarose and incubated at 37 °C until the lytic bands correlating to the PA-activity 
became visible.  A lysis resistant band indicated the migration of PAI-1. 
Analysis of membrane-bound PA activity was performed essentially as 
described (Stoppelli et al., 1986). Endothelial cells were washed with 0.2% BSA 
in PBS, pH 7.4, and treated with 50 mM Glycine-HCl buffer, pH 3.0, containing 
0.1 M NaCl at room temperature for 10 min. The buffer was collected, 
immediately neutralized, and subjected to casein zymography.  
Immunoprecipitation 
Cells were lysed with RIPA-DOC lysis buffer (50 mM Tris-HCl buffer, pH 
8.0, containing 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% sodium 
deoxycholate, 10 mM EDTA, 10 µg/ml aprotinin, 1 µg/ml pepstatin A, 1 µg/ml 
aminoethylbenzene sulphonyl fluoride, 1 mM sodium orthovanadate, and 10 mM 
sodium fluoride) and subjected to immunoprecipitation. Cell lysates were 
preabsorbed by incubation with preimmune serum and Gamma-bind Sepharose 
(Amersham Pharmacia, Uppsala, Sweden) at 4 ºC in an end-over mixer for 2 h. 
The beads were removed by centrifugation and the supernatants were incubated 
with the indicated antibodies on ice for 1 h. Gamma-bind Sepharose was then 
added and the samples were incubated in an end-over mixer at 4 ºC for 1 h. The 
beads were subsequently collected by centrifugation and washed three times with 
RIPA-DOC buffer. The bound proteins were eluted with Laemmli´s sample buffer 
at 95 ºC and separated by SDS-PAGE (4-15% acrylamide monomer gradient), 
transferred onto nitrocellulose and subjected to immunoblot analysis. Intensity of 
the detected bands was quantified from scanned immunoblots using Adobe 
Photoshop software. 
Immunofluorescence  
Cells cultured on glass coverslips were washed with PBS and fixed with 3 % 
paraformaldehyde at 4 ºC for 10 min. When required, the cells were permeabilized 
with 0.2 % Triton X-100 in PBS for 3 min. Nonspecific protein binding sites were 
then saturated with 5 % BSA in PBS for 30 min. The cells were then washed with 
PBS, and incubated with antibodies for 1 h. Rhodamine-conjugated phalloidin 
(Sigma) was used for the staining of the actin cytoskeleton. Unbound proteins 
were removed by washing, followed by incubation with fluorescein isothiocyanate 
or rhodamine -labeled secondary antibodies (Jackson ImmunoResearch 
Laboratories, West Grove, PA) for 1 h. The coverslips were finally washed and 
mounted on glass slides using Vectashield (Vector Laboratories, Burlingame, 
CA). The fluorescent images were obtained using an epifluorescent microscope 
and logarithmic image aquisition. 
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Cell adhesion assays 
Plastic 96-well cell culture plates were coated with endostatin or endostatin-
derived peptides at concentrations indicated (50 µl/well) at 4 °C for 16 h. 
Nonspecific adhesion sites were saturated by incubating the wells with 1 % heat 
inactivated BSA at 22 °C for 1 h. After washing the wells with PBS, 0.5x105 cells 
in 100 µl of prewarmed serum free medium were seeded into each well. After 90 
min of incubation at 37 °C, nonattached cells were removed by washing with 
PBS. The cells were then fixed and stained in 30 % methanol, 10 % acetic acid 
containing 0.1 % Coomassie Blue. Subsequently, the cells were washed 
extensively with 30 % methanol, 10 % acetic acid and once with PBS. The cells 
were then lysed in 1 % SDS, after which the amount of lysed cells were quantified 
by measuring their absorbance at 620 nm using a Multiscan plate reader 
(Labsystems, Finland). 
In vitro chemotaxis assay 
Cell migration assays were performed in modified Boyden chambers 
containing polyethylene membranes (8 µm pore size; BD Falcon, Franklin Lakes, 
NJ) coated with 50 µg/ml fibronectin at 4 ºC for 16 h. After washing the 
membranes with PBS, nonspecific adhesion sites were saturated with 1 % heat 
inactivated BSA at 22 ºC for 1 h. Cells suspended in serum free medium at a 
concentration of 5x103/ml were placed in the upper compartment of the chambers. 
Medium containing 50 ng/ml bFGF was added to the lower compartment. The 
chambers were then incubated at 37 ºC for 4 h. Subsequently, the membranes 
were fixed and stained in 30 % methanol, 10 % acetic acid containing 0.1 % 
Coomassie Blue. The cells migrated to the lower surface were counted at 200x 
magnification. Three random fields from each pair of wells were counted. Values 
represent three independent experiments. 
Isolation of the extracellular matrix 
Extracellular matrices were prepared according to (Hedman et al., 1979). 
Cells were seeded on plastic culture dishes in serum-containing culture medium 
and allowed to attach for 1 h. After this the medium was withdrawn and replaced 
with serum free medium containing endostatin or various chemicals at 
concentrations indicated. After 4 h of incubation the cells were washed with PBS 
and treated three times with 0.5 % sodium deoxycholate in 10 mM Tris-HCl 
buffer, pH 8.0, for 10 min. Subsequently, the plates were washed with PBS and 
allowed to dry. The resulting extracellular matrices were extracted in reducing 
Laemmli´s sample buffer, solubilized by boiling and separated by SDS-PAGE. 
The proteins were then transferred onto nitrocellulose and detected by 
immunoblot analysis. 
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Isolation of detergent-insoluble membrane fractions  
Cells were lysed in 1 % Triton X-100 in MES-buffered saline (25 mM MES, 
150 mM NaCl, pH 6.5). Cell extracts were homogenized using a 22 G needle and 
adjusted to a final density of 40 % by the addition of OptiPrep Density Gradient 
Medium (Sigma). Samples were then placed in a centrifuge tube and overlaid with 
a discontinuous 30 % / 5 % OptiPrep density gradient. Samples were then 
centrifuged at 39,000 rpm for 18 h, after which 1-ml fractions were collected and 
analyzed by immunoblotting as described previously (Taipale et al., 1992). 
Affinity precipitation of GTP-Rho 
Affinity precipitation of GTP-Rho. GTP-Rho affinity precipitation assays 
were performed essentially as described earlier (Ren et al., 1999). HDMECs 
treated with the indicated chemicals were washed with ice-cold Tris-buffered 
saline and lysed in 50 mM Tris-HCl buffer, pH 7.2, containing 500 mM NaCl, 10 
mM MgCl2, 1 % Triton X-100, 0.5 % sodium deoxycholate, 0.1 % SDS, 10 µg/ml 
leupeptin, 10 µg/ml aprotinin, and 100 µg/ml aminoethylbenzene sulphonyl 
fluoride. The lysates were then incubated with Rhotekin Rho Binding Domain-
agarose (Upstate Biotechnology Inc., Lake Placid, NY) at 4 °C for 45 min and 
washed three times with 50 mM Tris-HCl buffer, pH 7.2, containing 150 mM 
NaCl, 10 mM MgCl2, 1 % Triton X-100, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 
and 100 µg/ml aminoethylbenzenesulphonyl fluoride. The bound proteins were 
eluted with Laemmli´s sample buffer, separated by SDS-PAGE and detected by 
immunoblotting using a monoclonal antibody against RhoA (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA). The intensity of the RhoA signal was 
quantified from scanned immunoblots using Adobe Photoshop software. 
Src family kinase autophosphorylation assay. 
HDMECs were lysed and subjected to immunoprecipitation with pan-Src 
antibodies (Src-2, Santa Cruz Biotechnology Inc., Santa Cruz, CA) as described 
above. The immunoprecipitates were washed three times with RIPA lysis buffer 
and twice with Src kinase buffer (20 mM Hepes, pH 7.35, 3 mM MnCl2). 
Autophosphorylation was initiated by adding 5 µCi of [γ-32P] ATP (5000 
Ci/mmol; Amersham Pharmacia Biotech) and carried out in 40 µl of kinase buffer 
at 30 ûC for 15 min. The reactions were terminated by adding 10 mM EDTA (final 
concentration) on ice. The pellets were then washed twice with lysis buffer 
followed by SDS-PAGE and autoradiography. Incorporated radioactivity was 




Cells were seeded on plastic culture dishes in complete culture medium and 
allowed to attach for 90 min. After washing, the cells were incubated with 
endostatin for 3 h in serum-free medium containing [35S]-methionine (80 µCi/ml, 
1175 Ci/mmol; Amersham Pharmacia Biotech, Uppsala, Sweden). Subsequently, 
aliquots of conditioned media were subjected to immunoprecipitation with 
antibodies against fibronectin as described above. The eluted polypeptides were 
separated by SDS-PAGE (4-15 % gradient) under reducing conditions and 
visualized by autoradiography. 
Wound-induced migration assay 
Confluent HDMECs on glass coverslips in complete culture medium were 
wounded with a sterile pipet tip and washed with serum free medium. The cells 
were treated with 50 ng/ml bFGF and with 50 nM endostatin or 50 nM endostatin 
in combination with sodium orthovanadate immediately after wounding and again 
after 12 h. After 24 h of incubation the cells were fixed with paraformaldehyde 
and subjected to immunofluorescence analysis as described above. The migration 
distance was measured using an inverted phase contrast microscope and 
UltraView 4.0 software (Perkin Elmer, Fremont, CA). The mean migration 
distances were calculated from three reference points on each coverslip by 
subtracting the distance between the migrating cell fronts measured after 24 h of 
incubation from that measured at the time of wounding.  
Endothelial cell tube formation assay 
24-well cell culture plates were coated with 200 µl growth factor-reduced 
Matrigel basement membrane matrix (BD Biosciences, Bedford, MA) and 
allowed to form a gel at 37 ºC for 45 min. The cells (4 x 105) were suspended in 
600 µl pre-warmed serum free Medium 199 containing endostatin or endostatin-
derived peptides. The cells were then seeded on Matrigel-coated plates, treated 
with 10 ng/ml bFGF and incubated at 37 ºC for 16 h. The cells were subsequently 
fixed, and tube formation was assessed using an inverted phase-contrast 
microscope. Tubular branches were counted from three random fields. The values 
represent the results of three independent experiments. 
 43
Results
Endostatin regulates the levels of secreted soluble uPA/PAI-1 
complex and induces changes in the cell surface localization of 
uPA and uPAR (I) 
At the beginning of these studies endostatin had been identified as a potent 
inhibitor of angiogenesis. Endostatin inhibited migration of endothelial cells, but 
had no effect on other cell types. As proteolytic systems have been implicated to 
play an important role in cell migration and invasion, it became of interest to 
characterize the effects of endostatin on uPA-mediated cell pericellular 
proteolysis. 
To analyze the effects of recombinant endostatin on the levels of soluble, 
secreted uPA and PAI-1, HDMECs were treated with increasing concentrations of 
endostatin. Analysis of the conditioned media using casein zymography indicated 
that uPA appeared mostly as a complex with PAI-1. The levels of this complex 
were significantly decreased in response to endostatin treatment. The effect 
became visible after 3 h of treatment and at concentrations of 500 ng/ml (25 nM) 
of endostatin. PAI-1 levels were also independently assessed using reverse 
zymography. The analysis revealed down-regulated levels of soluble secreted 
PAI-1 in endostatin-treated cells. The decrease in uPA and PAI-1 levels did not 
involve changes in the corresponding mRNA levels of these proteins. 
To further characterize the endostatin-induced changes in uPA/PAI-1 levels, 
we analyzed the levels of cell-surface associated uPA/PAI-1-complexes. Casein 
zymography analysis of acid-eluted cell surface-bound proteins revealed a marked 
increase in the levels of uPA/PAI-1 complexes of endostatin-treated cells. 
Blocking the cell surface receptor uPAR by monoclonal antibodies inhibited the 
accumulation of uPA/PAI-1 complexes on the cell surface. This was observable 
both in untreated control cells and endostatin-treated cells indicating that uPAR is 
involved in the endostatin-induced accumulation of uPA/PAI- complexes on the 
cell surface. 
In addition to the controlled secretion of soluble proteases, pericellular 
proteolysis is tightly regulated through localization of the proteases to specific 
cellular compartments (Blasi and Carmeliet, 2002). To address the possible 
endostatin-induced changes in the localization of uPA and uPAR, 
immunofluorescence analysis was carried out. Under basal conditions, both of the 
proteins were found to localize in focal adhesions. In response to endostatin 
treatment, uPA and uPAR became redistributed, acquiring a diffuse cell surface 
localization. 
 44
Loss of focal adhesions and actin cytoskeleton in endostatin-
treated endothelial cells (I, II, III) 
Focal adhesions and actin stress fibers are functional protein complexes 
involved in cell adhesion and migration (Burridge and Chrzanowska-Wodnicka, 
1996; Gumbiner, 1996). Since endostatin was observed to induce redistribution of 
uPA and uPAR from focal adhesions, we sought to investigate the effect of 
endostatin treatment on focal adhesions. Immunofluorescence analysis of focal 
adhesion proteins vinculin and paxillin revealed that focal adhesions were rapidly 
disassembled in response to endostatin treatment. This effect was reversible, as 
focal adhesion plaques reappeared after 6 h of treatment.   
Association of endostatin with α5β1 integrin and caveolin-1 (II, III) 
Previous results had indicated that immobilized endostatin mediates 
endothelial cell adhesion via interaction with integrin α5β1 (Rehn et al., 2001). To 
investigate whether soluble endostatin binds to α5β1 integrin and whether this 
interaction affects the cell surface localization of this adhesion receptor, co-
immunoprecipitation and immunofluorescence analyses was carried out. We 
observed that endostatin treatment induced redistribution of α5β1 integrin into 
clusters distinct from focal adhesions. These clusters colocalized with caveolin-1 
staining. In addition, endostatin and caveolin-1 were found to co-
immunoprecipitate with α5β1 integrin. The interaction between caveolin and 
integrin α5β1 was dependent on the concentration of endostatin administered to 
the cells. 
Tyrosyl phosphatase-dependent activation of caveolin-1- 
associated Src regulates endostatin-induced disassembly of 
cytoskeleton and decreased deposition of fibronectin matrix (II) 
Phosphorylation signals generated as a result of growth factor stimulation or 
through interaction with the surrounding matrix or adjacent cells regulate cellular 
events such as the assembly and disassembly of focal adhesions and 
reorganization of the actin cytoskeleton (Giancotti and Ruoslahti, 1999; Schwartz 
and Baron, 1999). As members of the Src family of membrane-associated tyrosine 
kinases are involved in integrin-mediated signaling and are thought to control 
actin stress fibers and focal adhesion turnover (Thomas and Brugge, 1997), we 
sought to determine the effect of endostatin on the tyrosine kinase activity of Src. 
Src activity is regulated via dephosphorylation of the inhibitory phosphorylation 
site Tyr-527 and phosphorylation of the activating Tyr-416 (Piwnica-Worms et 
al., 1987). In vitro kinase assays revealed an increase in the autophosphorylation 
activity of the fraction of Src associated with caveolin-1 in response to endostatin 
treatment. An increase in the amount of Src phosphorylated at the activating Tyr-
416 was also observed using immunoblot analysis. The increase in activity was 
dependent on tyrosine phosphatase activity, since the tyrosyl phosphatase 
inhibitor orthovanadate inhibited these effects. 
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To investigate whether the effects of endostatin on actin stress fibers and 
focal adhesions would involve tyrosyl dephosphorylation, we administered the 
phosphatase inhibitor orthovanadate to HDMECs in combination with endostatin 
and analyzed cytoskeletal structures using immunofluorescence. Cells treated with 
endostatin in combination with orthovanadate displayed intact focal adhesions and 
actin stress fibers, whereas in cells treated with endostatin alone these structures 
were disrupted. 
To determine whether the disruption of actin stress fibers and focal adhesions 
was due to increased activity of Src, we treated the cells with endostatin in 
combination with PP1, a specific inhibitor of Src family kinases (Hanke et al., 
1996). Loss of actin stress fibers and focal adhesions were seen in cells treated 
with endostatin or PP1 alone, but in cells treated with both of the chemicals intact 
cytoskeletal structures were observed. 
Both α5β1 integrins and Src kinase are involved in the regulation of 
fibronectin matrix assembly. Since endostatin binds α5β1 integrin and increases 
Src activity, we sought to investigate the effect of endostatin on the deposition of 
the fibronectin matrix. Both immunoblot and immunofluorescence analyses of the 
deoxycholate-insoluble ECM deposited by the endostatin-treated endothelial cells 
revealed a decrease in fibronectin deposition compared to untreated control cells. 
This was not due to decreased secretion of soluble fibronectin. In contrast, an 
increase in the levels of soluble fibronectin was observed in the conditioned media 
of endostatin-treated cells. 
Endostatin and α5β1 integrin partition in lipid rafts in a heparan 
sulfate proteoglycan-dependent manner (III) 
Lipid rafts are specialized membrane microdomains enriched in 
glycosphingolipids and cholesterol, which serve as scaffolds for the recruitment of 
transmembrane proteins and intracellular signaling molecules at the plasma 
membrane (Simons and Ikonen, 1997). Caveolin is a major constituent of a 
subclass of lipid rafts. To investigate whether the previously observed interaction 
of endostatin with caveolin-1 involves the association of endostatin with the lipid 
rafts, we isolated Triton-X insoluble membrane fractions of cells treated with 50 
nM endostatin (1 µg/ml) using a discontinuous OptiPrep density gradient. We 
found that a fraction of endostatin localized in the caveolin- and glypican-1-
enriched top fractions of the flotation gradient, indicating raft localization. 
Transferrin receptor was used as a marker for the non-raft fractions. 
Treatment of cells with heparinase III (5 mU/ml) for 30 min, prior to the 
addition of endostatin to remove the cell surface exposed heparan sulfates, 
significantly reduced the amount of endostatin associated with the low-density 
fractions without appreciably affecting the levels of endostatin associated in the 
non-raft fraction. This indicated that heparan sulfate proteoglycans mediated the 
raft localization of exogenous endostatin. Further support for this finding was 
provided by the observed loss of the heparan sulfate-containing form of glypican-
1 from the raft fractions after heparinase III treatment. Chondroitin sulfate 
treatment was used as a negative control. 
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To investigate the role of α5β1 integrin in the cell surface association of 
endostatin, recombinant endostatin (1 µg/ml, 50 nM) was preincubated with 
purified soluble α5β1 integrin (5 µg/ml, 33 nM) for 12 h to saturate the putative 
integrin binding sites of endostatin. Solid-phase ligand binding analysis revealed 
that immobilized, purified α5β1 integrin bound endostatin in a saturable and dose-
dependent manner, and that saturation was reached beyond the 50 nM 
concentration of endostatin. Endostatin preincubated with soluble integrin α5β1
displayed decreased association with both high- and low-density fractions of the 
endothelial cell membrane. Non-interacting soluble α3β1 integrin was used as a 
negative control. 
Very low levels of α5β1 integrin were visible in the raft fraction of the 
untreated control cells, while the non-raft fraction displayed intensive staining. In 
endostatin treated cells, the levels of α5β1 integrin in the raft fraction were 
increased. Quantification of the immunoblots revealed an >2-fold increase in the 
ratio of raft versus non-raft associated integrins in response to endostatin 
treatment. When cells were pretreated with heparinase III (5 mU/ml) for 30 min 
prior to the addition of endostatin, the amount of α5β1 integrin in the raft fraction 
was decreased to the level of control cells. 
Importantly, inhibition of lipid raft formation using the cholesterol-binding 
agent filipin III or cholesterol chelating agent methyl-β-cyclodextrin inhibited the 
trans-localization of endostatin into the raft fraction. In addition, 
immunofluorescence analysis revealed that interaction of endostatin with lipid 
rafts, α5β1 integrin, as well as an unidentified heparan sulfate proteoglycan were 
required for the endostatin-induced disassembly of the actin cytoskeleton.  
Endostatin downregulates RhoA activity via Src and p190 (III) 
RhoA activity induces the formation of focal adhesions and actin stress fibers 
(Ridley and Hall, 1992). To investigate whether changes in RhoA activity were 
associated with the endostatin-induced disassembly of focal adhesions and actin 
stress fibers, RhoA activity assays were carried out. These experiments revealed a 
dose-dependent decrease in RhoA activity in response to endostatin treatment. 
The Src inhibitor PP1 could partly reverse this inhibition. 
Src regulates Rho activity by tyrosine phosphorylation of p190RhoGAP, a 
GTPase activating protein with high specificity for Rho (Arthur et al., 2000; 
Ridley et al., 1993). Endostatin treatment led to an increase in the tyrosine 
phosphorylation of p190RhoGAP. This effect could also be inhibited using PP1. 
Endostatin-derived peptides promote cell adhesion via integrins 
and induce disassembly of the cytoskeleton (IV) 
The crystal structure of mouse endostatin revealed a compact globular fold 
and a basic patch of 11 arginine residues, which have been suggested to act as 
binding sites for heparin (Hohenester et al., 1998; Sasaki et al., 1999). To define 
its critical cell interaction domains and to investigate the role of the basic amino 
acids for endostatin function we constructed endostatin-derived synthetic peptides 
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containing 12 out of the total 18 surface exposed basic amino acids. When 
immobilized, an arginine-rich peptide of 11 amino acids, termed ES-2, efficiently 
promoted endothelial cell adhesion. Antibodies against β1 integrin as well as 
heparin efficiently inhibited endothelial cell adhesion to this peptide. Peptides ES-
3 and ES-5 also promoted cell adhesion. Heparin efficiently inhibited cell 
adhesion to these peptides, while antibodies against α5 or β1 integrins had no 
effect. 
Actin staining of cells attached on ES-2 revealed the formation of membrane 
ruffles at the cell periphery. No formation of actin stress fibers was observed. The 
actin-rich membrane protrusions were also positive for vinculin staining. Integrin 
α5β1 was also observed to localize to the membrane ruffles in the cell periphery. 
Cells plated on ES-2 displayed limited cell spreading when compared to cells 
plated on fibronectin, the major substrate for α5β1 integrin. 
When soluble, the ES-2 peptide induced the loss of focal adhesions and actin 
stress fibers in these cells. Substitution of the arginine residues with alanines 
resulted in the loss of these properties. 
Endostatin-derived peptides inhibit endothelial migration and 
tubular morphogenesis of endothelial cells (IV) 
Since the endostatin-derived peptides induced changes in cell-matrix 
interactions, we explored next their effects on directional cell motility using a 
modified Boyden chamber assay. Cell migration through a fibronectin matrix 
towards bFGF was inhibited approximately 50 %, when the endothelial cells were 
treated with 500 nM ES-2 peptide. This was comparable with the effect of 50 nM 
full length endostatin. The mutated peptide lacking all of the arginine residues did 
not affect cell migration. 
To assess the effect of the endostatin-derived peptides on the formation of 
vascular structures, HDMECs were seeded on growth factor reduced Matrigel 
basement membrane matrix in the presence of bFGF. In cells treated with 50 nM 
endostatin or 500 nM ES-2 peptide, tube formation was significantly decreased 
and the cells remained as an adherent monolayer with only a few tubelike 
structures. The mutated peptide lacking all of the arginine residues had no 
inhibitory effect on the tubular morphogenesis of HDMECs. 
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Discussion
The process of angiogenesis is regulated by shifts in the balance between 
endogenous pro- and anti-angiogenic factors. When this work was initiated, 
endostatin, a novel negative regulator of angiogenesis, had been identified and 
characterized (O'Reilly et al., 1997). Further studies elucidated several possible 
cell biological mechanisms underlying the anti-angiogenic effects of endostatin. 
These included inhibition of endothelial cell migration, induction of cell cycle 
arrest, and promotion of apoptosis (Dhanabal et al., 1999; Dixelius et al., 2000; 
Hanai et al., 2002a; O'Reilly et al., 1997). The current work contributes to the 
effort of understanding the basic cell biological mechanisms underlying anti-
angiogenic effects of endostatin in vivo. The central findings of this study are the 
following: (1) endostatin regulates pericellular proteolysis by downregulating the 
levels of secreted uPA and PAI-1, and by increasing the levels of uPA/PAI-1 
complex bound to uPAR at the cell surface; (2) endostatin induces disruption of 
the actin cytoskeleton and loss of focal adhesions via Src-dependent activation of 
p190 and inactivation of RhoA; (3) endostatin signaling is dependent on lipid raft 
microdomains, and involves interactions with α5β1 integrins as well as cell surface 
heparan sulfate proteogycans; (4) identification of an endostatin-derived synthetic 
peptide, which interacts with α5β1 integrins and modulates the actin cytoskeleton 
and endothelial cell migration. 
Effects of endostatin on endothelial cell pericellular proteolysis 
Proteolytic activity is an important process during endothelial cell sprouting 
and tube formation (Koolwijk et al., 1996; Risau, 1997). In this work, pericellular 
proteolytic activity was observed to be redistributed and down-regulated in 
response to endostatin treatment (I). Several studies have indicated a role for 
plasminogen activators in tumor-associated neovascularization, primary tumor 
growth, and metastasis (Crowley et al., 1993; Min et al., 1996; Ossowski, 1996). 
For efficient proteolysis, proteases are targeted to distinct locations at the cell 
surface and, in particular, changes in uPA and PAI-1 secretion and localization 
can induce changes in cell migration and adhesion (Deng et al., 1996; Planus et 
al., 1997; Yebra et al., 1996). Endostatin induced the translocation of uPA/uPAR 
from focal adhesion structures into a diffuse cell surface localization. At the same 
time, the uPA/PAI-1 complexes isolated from the cell surface by acid treatment 
were increased in a dose-dependent manner. Interestingly, no intracellular or 
matrix accumulation of these proteins was observed (I). Interactions with various 
transmembrane proteins are crucial for the function of uPAR. The internalization 
of the uPA/PAI-1/uPAR complexes is mediated via interaction with the low-
density lipoprotein-receptor-related protein (Czekay et al., 2001). The increased 
levels of this complex at the cell surface could be a consequence of its 
displacement from the focal adhesions, as the subcellular localization of uPAR is 
critical in determining its interaction partners. The relocalization could result in 
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altered internalization and recycling of the proteinase complex. Inhibition of 
uPAR internalization results in the increase in the levels of cell surface uPA/PAI-
1 complexes. This is associated with decreased recycling of unoccupied uPAR to 
the cell surface with concomitant decrease in the migratory capacity of the cell 
(Degryse et al., 2001; Li et al., 2002). The relocalization of uPA and uPAR 
induced by endostatin may be a consequence of the focal adhesion disassembly, or 
an independent effect. 
The levels of secreted uPA and PAI-1 were decreased in endothelial cells 
after endostatin treatment. However, no changes in the mRNA levels of uPA or 
PAI-1 were observed (I). The mechanism by which the post-transcriptional 
regulation of plasminogen activator levels by endostatin occurs is currently not 
understood. It is possible that the altered distribution and increased levels of 
uPA/PAI-1 on the cell surface could be linked to the decreased secretion of these 
proteins. Cell adhesion on a specific ECM ligand, such as vitronectin, directly 
regulates the secretion of uPA and influences its localization into focal adhesions 
(Wilcox et al., 1996). This suggests that an extensive network of crosstalk exists 
between secreted and uPAR-bound uPA/PAI-1 complexes, cell adhesion and 
migration. 
Regulation of actin cytoskeleton and cell migration by endostatin 
The speed of cell migration is determined by the strength of cell adhesion to 
the ECM. On the other hand, the direction of the motility is controlled by growth 
factors such as bFGF, which in coordination with cell adhesion molecules 
enhance cell polarity (Eliceiri, 2001). We observed that treatment of endothelial 
cell monolayers with soluble endostatin resulted in the loss of focal adhesions and 
actin stress fibers (I-IV). Disruption of actin stress fibers and focal adhesions by 
endostatin could result in decreased adhesion and increased random migration. On 
the other hand, the loss of these structures at the leading edge could inhibit 
directional migration towards a chemotactic stimulus. Various other endogenous 
inhibitors of angiogenesis target the endothelial cell cytoskeleton. 
Thrombospondin-1 interacts with the cell surface receptors CD36 and heparan 
sulfate proteoglycan, and induces the disassembly of actin stress fibers and focal 
adhesions (Dawson et al., 1997; Orr et al., 2002). Angiostatin, the antiangiogenic 
fragment of plasminogen, induces actin stress fiber reorganization via ceramide 
and RhoA (Gupta et al., 2001; O'Reilly et al., 1994). Like endostatin, these 
proteins negatively regulate endothelial cell migration (Dawson et al., 1997; 
O'Reilly et al., 1994; Troyanovsky et al., 2001). 
Protein phosphorylation and dephosphorylation serve as molecular switches 
in the control of the migration-associated assembly and disassembly of focal 
adhesions and actin stress fibers (Burridge and Chrzanowska-Wodnicka, 1996). 
Important regulators of these phosphorylation events are the Src family kinases 
that are activated by integrin ligand binding. Their kinase activity directly 
regulates the turnover of the cytoskeletal structures (Thomas and Brugge, 1997). 
We observed that endostatin treatment lead to increased activation of a Src kinase 
directly associated with caveolin-1. Consequently, the endostatin-induced 
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disassembly of focal adhesions and actin stress fibers was antagonized by the Src 
inhibitor PP1, which alone is capable of inducing disassembly of the cytoskeleton 
(II). 
In addition, we observed Src dependent activation of p190RhoGAP by 
endostatin (III). This occurred in parallel with Src dependent downregulation of 
the small GTPase RhoA (III). Src-mediated transient downregulation of RhoA 
activity, accompanied by the disassembly of the cytoskeleton has also been 
observed to be an initial event following ligand binding of integrins This process 
promotes efficient cell spreading and is followed by an increase in Rho activity, 
resulting in reformation of actin stress fibers and focal adhesions (Arthur et al., 
2000). However, the kinetics of both the activation of Src as well as the 
downregulation of RhoA activity were significantly slower than that resulting 
from the interaction of ECM-deposited fibronectin with integrin α5β1 (Arthur et 
al., 2000). This suggests that the downstream signaling induced by endostatin is 
not completely analogous to that of other ECM ligands binding integrins. Rho 
possesses a dual role in the regulation of cell migration. High levels of active Rho 
promote cell adhesion to the substrate, which decreases cell motility. On the other 
hand, decreased levels of Rho activity inhibit cell motility, possibly through 
reducing membrane ruffling and tail-retraction of the migrating cell, and delaying 
the turnover of actin stress fibers and focal adhesions (Nobes and Hall, 1999; 
Ridley et al., 1995; Santos et al., 1997). Since endostatin induces reversible loss of 
stress fibers persisting for several hours (I), the endostatin-induced 
downregulation of RhoA could significantly reduce the speed of endothelial cell 
migration by delaying the dynamics of actin stress fiber and focal adhesion 
turnover.
Since our primary observation of endostatin-induced disassembly of actin 
stress fibers and focal adhesions, several studies have provided further evidence of 
the actin cytoskeleton to be regulated by endostatin treatment. By comparing two-
dimensional gel electrophoresis patterns of endostatin-treated and untreated cells, 
heat shock protein 27 (hsp27) and cofilin were identified as targets for endostatin 
(Keezer et al., 2003). Hsp27 regulates actin polymerization, and the 
phosphorylation of hsp27 is associated with changes in the actin cytoskeleton in 
VEGF-stimulated endothelial cell motility (Rousseau et al., 1997). Endostatin 
induced phosphorylation of hsp27 and cofilin, accompanied by an increase in 
actin stress fibers and paxillin-positive focal adhesions (Keezer et al., 2003). 
Interestingly, RhoA activity phosphorylates and inactivates cofilin, leading to the 
stabilization of actin stress fibers (Worthylake and Burridge, 2003). 
In another study, endostatin was observed to induce the formation of actin 
stress fibers and focal adhesions in the absence of bFGF, but when the growth 
factor was present, disassembly of these structures was observed (Dixelius et al., 
2002). This suggests that the apparent differences on the effects of endostatin on 
the cytoskeleton may arise from differences in the cell culture conditions before 
and during treatment, as well as from variation in the endogenous production of 
growth factors by different endothelial cell lines. 
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Requirement of integrin α5β1, heparan sulfate proteoglycans and 
lipid rafts in endostatin signaling 
When this work was initiated, two putative receptors for endostatin had been 
identified. Studies using bovine pulmonary arterial endothelial cells indicated, that 
endostatin binds endothelial cells with two distinct affinities, a high-affinity Kd of 
18 pM (1.7 x 104 binding sites/cell) and a lower-affinity Kd of 200 pM (8.4 x 104
binding sites/cell). The low-affinity receptor was identified as the heparan sulfate 
proteoglycan glypican. Endostatin also binds to renal tubular epithelial cells via 
this receptor (Karumanchi et al., 2001). Glypican-4 is highly expressed in the 
developing brain and is the major glypican expressed in renal tubular cells, 
whereas the predominant glypican in endothelial cells is glypican-1 
(Gengrinovitch et al., 1999; Watanabe et al., 1995). Glypican-1 expression is 
critical for endostatin inhibition of VEGF-induced endothelial cell migration, 
indicating that it is a functional receptor for endostatin. Interaction of endostatin 
with glypican seems to be necessary for its subsequent binding to the high-affinity 
site, suggesting that heparan sulfate proteoglycans present endostatin to another 
cell surface receptor. The high-affinity receptor was not identified (Karumanchi et 
al., 2001). 
Cell adhesion on immobilized endostatin is mediated mainly by α5β1 and in 
part by αvβ3 integrins (Rehn et al., 2001). In this context, endostatin acts as an 
integrin ligand promoting cell adhesion, formation of focal adhesions and actin 
stress fibers and inducing tyrosine phosphorylation (Rehn et al., 2001). Another 
study confirmed that α5β1 integrin serves as a functional receptor also for soluble 
endostatin, and that the anti-migratory effects of endostatin are transduced in an 
integrin-dependent manner (Sudhakar et al., 2003). 
We observed that endostatin associated directly with α5β1 integrin and the 
membrane scaffold protein caveolin-1 (II). In addition, α5β1 integrin directly 
mediated the cell surface association of endostatin. Heparan sulfate proteoglycans, 
on the other hand, mediated the translocation of endostatin and α5β1 integrin into 
lipid raft microdomains. Both of these interactions as well as the lipid raft 
microdomain per se were necessary for the cytoskeletal rearrangement induced by 
endostatin (III). Taken together, these findings imply that both heparan sulfate 
proteoglycans as well as α5β1 integrins act as functional receptors for endostatin. 
The signaling functions of endostatin are probably mediated via α5β1 integrin. 
Heparan sulfate proteoglycans act as coreceptors, presenting endostatin to 
integrins and regulating the localization of the endostatin-integrin complex into 
membrane rafts. Glypican belongs to the GPI-anchored proteins, which are a 
major class of proteins in the lipid rafts (Brown and Rose, 1992; Mayor et al., 
1994). In addition, membrane lipids and raft microdomains have been observed to 
regulate integrin and integrin-associated protein activity (Green et al., 1999; 
Pande, 2000). 
The presence of caveolin-1 in a complex with endostatin and integrin α5β1
suggest a role for caveolae, which are a specialized subclass of lipid rafts, in the 
effects of endostatin. Integrins are generally considered not to localize in caveolae 
(Lisanti et al., 1994). However, it has been suggested that caveolae serve as 
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temporary scaffolding domains for clusters of integrins, caveolin-1 and Src 
kinases, and that these structures are disassembled in response to integrin 
engagement by insoluble ECM ligands and subsequent recruitment to focal 
adhesions (Wei et al., 1999). An open question remains whether the lipid raft 
localization results in the internalization of endostatin via caveolae or a related 
raft pathway, and whether the internalization is required for the cell biological 
effects of endostatin. Some endothelial cell types apparently internalize 
recombinant endostatin, but the functional consequences of this process have not 
been characterized further (Dixelius et al., 2000). 
Identification of an integrin-binding peptide within endostatin 
The structure of endostatin is characterized by a compact globular fold and a 
basic patch of 11 clustered arginine residues, which have been suggested to act as 
binding sites for heparin (Hohenester et al., 1998; Sasaki et al., 1999). The roles of 
the arginine residues are unclear, since both decreased and unaltered anti-
migratory potential has been reported in endostatin mutants unable to bind heparin 
(Sasaki et al., 1999; Yamaguchi et al., 1999). In addition, endostatin binds 
integrins, but no specific integrin-binding sites have been identified so far. The 
ligands of α5β1 integrins consist of ECM or cell surface proteins containing the 
RGD-sequence (Ruoslahti, 1996), but both mouse and human endostatins lack this 
sequence motif. 
In the current study we observed that peptides derived from areas of human 
endostatin containing multiple surface exposed basic amino acid residues were 
able to promote endothelial cell adhesion and spreading via both heparin- and 
integrin β1-dependent interactions. In contrast to the integrin ligand fibronectin, 
which contains the RGD-sequence, ES-2 peptide promoted only a limited degree 
of cell spreading and did not induce the formation of actin stress fibers or 
abundant cytoplasmic focal adhesions (IV). These observations imply that the 
binding of endostatin or ES-2 peptide to the integrin could occur at a site distinct 
from the ligand binding pocket. On the other hand, endostatin exists as a 
monomer, and monovalent ligand occupancy of integrins is apparently insufficient 
for efficient accumulation of cytoskeletal proteins (Miyamoto et al., 1995). 
Adhesion of endothelial cells to full-length endostatin has been suggested, 
however, to occur in an RGD-dependent manner. Cyclic RGD peptides inhibit the 
attachment of human umbilical endothelial cells to fibronectin and also 
endostatin-coated plates. This implies that endostatin competes for the RGD 
binding sites within fibronectin (Sudhakar et al., 2003). We did not observe 
significant inhibition of endothelial cell adhesion on fibronectin by the ES-2 
peptide or endostatin (IV). In addition to integrins, the adhesion of endothelial 
cells to ES-2 occurred in part via a mechanisms involving heparin (IV). The 
activity was critically dependent on the specific arginine residues within the 
peptides, which have been reported to be crucial for the heparin binding as well as 
the anti-migratory activity of endostatin. This finding further supports the 
conclusion that heparan sulfate proteoglycans may act as co-receptors for 
endostatin.
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Synthetic peptides from other regions of full-length endostatin have been 
observed to contain anti-angiogenic activity. A peptide containing amino acids 6-
49 is capable of inhibiting human umbilical vein-derived endothelial cell 
proliferation and migration, and is also effective in inhibiting angiogenesis in vivo 
(Chillemi et al., 2003). In that report, no activity was observed for the 42 aa 
peptide covering the amino acids 50-92, although it contains the sequence for the 
ES-2 peptide (11 aa) used in the current study. The variation between the results 
of the two studies may be a result of differences in the biochemical properties of 
peptides of different lengths. Studies using peptide fragments from another 
basement membrane-derived angiogenesis inhibitor, tumstatin, suggest that the 
length of the peptide is a critical determinant of biological activity. This is most 
likely due to differences in the secondary structure of the peptides and in their 
propensity to form aggregates (Floquet et al., 2003). The folding and aggregation 
of the peptides is likely to affect the exposure of specific aa residues, and thus 
mask putative cell surface interaction sites. 
A model for endostatin-induced signaling 
Endostatin has been reported to induce a plethora of intracellular signals, 
which regulate multiple aspects of endothelial cell behavior. The large variation in 
the observed effects may be a result of multiple factors. The endostatin used in 
both the in vivo and in vitro studies is derived from various sources. It has been 
produced as an insoluble precipitate in E. coli or as a soluble protein in Pichia
pasteuris or a baculoviral expression system. The soluble and insoluble 
endostatins seem to differ in their biochemical properties and cell biological 
effects (Kranenburg et al., 2003). In addition, the cell culture models used in the 
studies range from macrovascular aortic endothelial cells to microvascular 
endothelial cells. Macro- and microvascular endothelial cells differ in various 
aspects, such as their responsiveness to growth factor stimulus (Lang et al., 2001; 
Lang et al., 2003). Unexpectedly wide range of concentrations have been used in 
various studies, ranging from 10 ng/ml to 10 µg/ml. Finally, human and mouse 
endostatins seem to have distinct cell biological effects, despite their close 
sequence homology (Sudhakar et al., 2003; Yamaguchi et al., 1999). 
The most consistent effect of human endostatin seems to be its ability to 
inhibit growth factor-induced endothelial cell migration. As endostatin does not 
affect the major intracellular pathways stimulated in growth factor-induced cell 
motility (Eriksson et al., 2003), it is probable that endostatin has a unique 
mechanism of action, by which it modulates endothelial cell migration. The 
modulation could occur via direct effects on endothelial cell - matrix interactions. 
The inability of endostatin to perturb major intracellular signaling pathways may 
also be associated with its lack of effect on the normal quiescent vasculature. This 
may also explain the low toxicity of these agents in the clinical trials (Dixelius et 
al., 2003). 
The results of the current study suggest that endostatin binds to α5β1 integrin 
on the cell surface. Its simultaneous or subsequent interaction with an unidentified 
heparan sulfate proteoglycan leads to the translocation of endostatin and α5β1
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integrin into lipid rafts, where they associate with caveolin-1. These interactions 
induce the activation of caveolin-associated Src tyrosine kinase. Src then 
phosphorylates and activates p190RhoGAP, which in turn induces the 
autocatalytic inactivation of RhoA. Finally, the decrease in RhoA activity leads to 
the disassembly of actin stress fibers and focal adhesions resulting in reduced 
migratory capacity of the endothelial cell (Fig. 6). Other putative mechanisms of 
decreased cell migration include the phosphorylation of FAK and subsequent 
rearrangement of the cytoskeleton as well as inhibition of FAK and the ERK/p38-
pathway (Dixelius et al., 2002; Sudhakar et al., 2003). 
Figure 6. Intracellular signaling by endostatin. Endostatin binds α5β1 integrin on the cell surface. 
Its simultaneous or subsequent interaction with a heparan sulfate proteoglycan (HSPG) leads to 
the association of endostatin, α5β1 integrin, and caveolin-1 (cav-1) in the lipid rafts. These 
interactions induce the activation of the fraction of Src tyrosine kinase that is associated with 
caveolin-1. Src then phosphorylates and activates p190RhoGAP, which in turn catalyzes the 
conversion of the active GTP-bound Rho into the inactive GDP-bound form. Finally, the 
downregulation of Rho activity leads to the disassembly of actin stress fibers and focal adhesions. 
Activation of FAK followed by disassembly of the actin cytoskeleton, as well as inhibition of FAK 
and ERK/p38 activity by endostatin have also been described. These signals result in reduced 
adhesive and migratory capacity of endothelial cells. 
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Perspective
Proteolytic fragments of the basement membrane collagens are a recently 
discovered group of endogenous inhibitors of angiogenesis. They are also novel 
pharmacological agents developed to target vascular endothelial cells and to 
inhibit pathological angiogenesis. Since its isolation in 1997, endostatin has been 
extensively studied, both in the laboratory and in the clinic. Animal studies have 
concluded that recombinant endostatin is capable of effectively reducing tumor 
volume, and both animal studies and phase I human trials have reported negligible 
toxicity. Despite the promising results of the in vivo studies, the mechanisms of 
endostatin action are far from clear. 
The results of the current study as well as previous data identify both heparan 
sulfate proteoglycans and α5β1 integrins as receptors for endostatin. These two 
proteins are expressed by multiple non-endothelial cell types in various tissues, 
but endostatin appears to function in a highly endothelial cell specific manner. A 
major question to be answered is which molecular mechanisms underlie this 
specificity. In addition, it is unclear, how endostatin associates with these cell 
surface receptors, and what are the precise molecular mechanisms by which the 
intracellular signals are generated. Determining the crystal structure of endostatin 
in complex with its putative integrin receptor would provide important 
information on the mechanisms of endostatin action. In addition, better 
understanding of the mechanisms of endostatin function could yield novel, more 
specific molecular targets for pharmacological intervention in disorders involving 
aberrant angiogenesis. 
The vascular BM provides not only structural support to the vessel wall, but 
is also a regulator of angiogenesis and tumor growth. Its components regulate cell 
fate differently when in assembled or degraded form. Despite the potency of 
recombinant endostatin to reduce tumor volume in experimental animal models, 
the exact biological roles of type XVIII collagen and its endostatin fragment are 
still unclear. Analysis of mice deficient of type XVIII collagen in conditions 
involving aberrant angiogenesis, such as cancer or rheumatoid arthritis, could 
bring valuable new information on the role of the endostatin fragment in the 
regulation of angiogenesis. 
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